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ABSTRACT 
 
Cardiac diseases such as coronary artery disease, hypertension and heart failure 
are the major causes of death around the world. Regulation of beta-adrenergic 
receptors by catecholamines is an important facet of understanding cardiac 
function in health and disease. Acute sympathetic activation of βARs results in an 
increase in cardiac output; however, sustained stimulation of the βARs is 
cytotoxic, leading to myocyte death and cardiac remodeling. β-adrenergic 
blockers are a seminal class of drugs that play an important role in improving 
mortality and symptom control in various cardiac diseases.   
An important transcriptional regulatory protein target of β-adrenergic signaling is 
MEF2, which plays a crucial role in cardiac gene expression during pathologic 
and physiological adaptation of the heart.  In our experiments, we have observed 
a robust effect of β-blockers on MEF2 transcriptional activity. Myocardial MEF2 
responses to β-blocker treatment indicates an important physiological linkage 
between β-adrenergic signaling and MEF2 activity in the heart, which underpins 
changes in cardiac gene expression in response to β-adrenergic blockade. In the 
first set of experiments, the link between MEF2 and cardiac survival pathways in 
the heart was examined. Initially, using flow cytometry we observed that levels of 
cell death are dramatically enhanced in cardiomyocytes when the expression of 
MEF2 is suppressed using siRNA technology. Also transcriptome analysis of 
siRNA-mediated gene silencing of MEF2 showed extensive apoptotic DEG define 
genes. Together these data indicate that MEF2 play a key role in cardiomyocyte 
survival. Furthermore, I demonstrated that β1AR mediated apoptosis was 
abrogated in cardiomyocytes expressing a PKA-resistant form of MEF2D 
(S121/190A). A β1-blocker, Atenolol, antagonizes isoproterenol-induced 
apoptosis while concomitantly enhancing MEF2 transcriptional activity. Kruppel-
like factor 6, a MEF2 target gene in the heart; functions as a downstream pro-
survival factor in cardiomyocytes. Collectively, these findings indicate a 
mechanism of the beneficial effects of acute β1AR blocker treatment through up-
regulation of MEF2 activity, leading to cardiomyocyte survival. In the second set 
of experiments, I studied changes in MEF2 activity and global gene transcription 
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networks during heart failure and in response to chronic β1-blockade in an in vivo 
model. First, β1-blockade treatment resulted in an overall improvement in cardiac 
function in Transverse aortic constriction mice co-incident with repression of 
MEF2 activity. Dynamic changes in gene expression activated by TAC were 
reversed by β1-blockade treatment. Transcriptome profiling in MEF2A depleted 
cardiomyocyte identified a novel MEF2 target gene, Rarres2, which is 
upregulated with TAC and isoproterenol and is involved in cardiac apoptosis. 
Together these data demonstrate that chronic β1-blockade inhibits myocardial 
MEF2 activity while also minimizing dynamic changes in HF associated 
transcriptome dynamics. Collectively, these data indicate molecular events 
resulting from β1-adrenergic blockade that result in positive effects on heart 
pathology. These studies define novel molecules and pathways involved in heart 
pathology that may represent new genetic or pharmacologic targets for heart 
failure therapies.  
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CHAPTER 1: Literature Review 
1. General overview 
          Regulation of gene expression is important in cell growth, differentiation and 
disease. Signal dependent regulation of gene expression is controlled by transcription 
factors. Cardiac transcription factors control the complex process of heart development 
and are also involved in stress regulation of the adult heart, which may lead to cardiac 
disease. Knowledge of the network of cardiac transcription factors that link the upstream 
signaling pathways to direct or indirect target genes lead us to a better understanding of 
the cause of cardiac disease 1,2. Cardiac disease activates pathological signaling 
pathways that target transcription factors and reprogram cardiac gene expression, 3 
which, then translated into production of proteins involved in contraction, calcium 
handling, and metabolism, leads to cardiac dysfunction. Therefore, the regulation of a 
network of transcriptional regulatory proteins in the heart is a primary determinant of its 
gene expression signature and phenotype 4. The clarification of these transcriptional 
networks is ongoing and has provided major steps in understanding the control of 
cardiac gene expression; however, the levels of control of transcriptional regulators by 
pharmacological manipulation is still not explained. Regulation of transcriptional 
regulatory protein by pharmaceutical manipulation can exert considerable control over 
the gene expression profile and consequently heart function. As mentioned above, 
regulation of transcription factors has indeed been a predominant theme in 
understanding the molecular control of physiology and pathology of the heart 4. A 
number of transcriptional regulators such as nuclear factor of activated T-cell (NFAT) 5,6,  
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the GATA family 7,8 and the myocyte enhancer family (MEF2) 9 have been identified as 
playing important roles in the heart via control of cardiac gene expression 10. 
Several studies reported the control of cardiac gene expression and the loss of function 
analysis in gene targeted mice have positioned MEF2 as a core transcription factor 
involved in cardiac physiological and pathological pathways 11. 
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2. MEF2 role and regulation 
 
2.1. MEF2 overview 
 
          The Myocyte Enhancer Factor-2 (MEF2) family of transcription factors play a 
central role in regulating cardiac 12, skeletal 13,14, and smooth muscle differentiation 15, 
neuronal survival and plasticity, 16,17 and T cell activation 18. MEF2 transcription factors 
belong to the evolutionarily ancient MADS (MCM1, Agamous, Deficiens, SRF) 
superfamily of DNA binding proteins. In vertebrates, there are four MEF2 genes 
(MEF2A, -B, -C, and –D) that are located on different chromosomes (Figure 1). By 
contrast, there is a single MEF2 gene in each of the genomes of Drosophila, 
Caenorhabditis elegans and Saccharomyces cerevisiae 19. The requirement for MEF2 is 
evolutionarily conserved for cardiac and skeletal muscle development from flies to 
humans 19.  
The N-terminus of MEF2 proteins is highly conserved among all family members and 
consists of a 57-amino acid MADS domain and an immediately adjacent 29-amino acid 
MEF2 domain. These two domains collectively mediate dimerization, co-factor 
interactions and DNA binding to the consensus DNA sequence (T/C) TA (A/T)4TA(G/A) 
20. The MEF2 transcriptional activation domain (TAD), which is divergent among family 
members, is positioned in the C-terminus of the protein and is subject to complex 
patterns of alternative splicing and extensive posttranslational modifications 21.  
MEF2 was originally identified in skeletal muscle cells as a DNA-binding factor that 
recognized a conserved A/T-rich sequence in the muscle creatine kinase (MCK) 
enhancer 22. The MEF2 binding sequence was identified in a majority of muscle specific 
genes that have been confirmed to be essential for gene expression 22. These MEF2-
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dependent genes encode a wide array of proteins, including structural proteins like α-
cardiac myosin heavy chain (α-MHC), myosin light chain 1/3 (MLC1/3), ventricular 
myosin light chain 2 (MLC2v), sarcoplasmic reticulum Ca2+ATPase (SERCA), cardiac 
troponin (-T, -C and –I), desmin, dystrophin and insulin sensitive glucose transporter 4 
(GLUT4) which regulates cardiac metabolism 23–27. 
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Figure 1. Schematic diagrams of MEF2 factors. Structures of the four vertebrate 
MEF2 gene products are shown. Alternative exons within the C-terminal activation 
domains are indicated, along with the number of amino acids in the longer form of each 
protein. This schematic has been adapted from 28. 
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2.2. MEF2 isoforms and their function in the heart 
          MEF2 is an essential regulator of cardiac morphogenesis and myogenesis. 
Previous studies showed that MEF2A knockdown in Zebrafish results in cardiac 
morphology defects, impairments of cardiac contractility and sarcomere assembly 29. In 
addition, expression of cardiac contractile genes, including Troponin C, Troponin T, 
atrial myosin heavy chain (aMHC) and cardiac myosin light chain 2 (MLC2) which are 
involved in cardiac contractile organization were down-regulated. The expression of 
MEF2D was upregulated, possibly to compensate for the loss of MEF2A protein 29. 
MEF2A and MEF2D are the primary MEF2 factors expressed in the adult heart. Mice 
deficient in MEF2A have post-natal dilation of the right ventricle, and deficiency of 
cardiac mitochondria and cardiac sudden death 30. On the other hand, MEF2D knockout 
mice are viable, but are resistant to cardiac hypertrophy and pathological remodeling of 
the heart induced by stress 31. Deletion of another MEF2 isoform, MEF2C, is associated 
with similar defects and myocardial impairment. MEF2C knockout mice die around E9.5 
from cardiac looping defects, and disruption in right ventricle formation 15. But the 
expression of MEF2B was enhanced, possibly to compensate for the loss of MEF2C 15. 
MEF2B knock out mice are viable and its absence could be compensated by either 
MEF2A or MEF2C in cardiac development 15. Thus, these studies clearly identify a 
functional role for MEF2 proteins in cardiac muscle cells development and cyto-
architectural integrity. 
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2.3. MEF2 regulation by signaling pathways in cardiac 
          MEF2 transcriptional regulatory proteins play an important role in cardiac gene 
expression during pathologic and physiological adaptation of the heart 32. Furthermore, 
MEF2 is crucial in activating diverse and often opposing genetic programs such as 
those that control cell proliferation, differentiation, morphogenesis, survival and 
apoptosis 33. These different roles for MEF2 transcriptional factors are partly explained 
by the mechanisms that exist to regulate their activity. Therefore, regulation of MEF2 
transcription factors by several kinase signaling cascades is important in understanding 
the molecular control of physiology and pathology of the heart.  
MAPK-dependent phosphorylation enhances MEF2 transcriptional activity. The p38 
MAPK is one of the MAPK phosphorylation cascades that can directly phosphorylate 
MEF2 and enhance its transcriptional activity (Figure 2) 34. Previous studies have shown 
that MEF2A and MEF2C were directly phosphorylated and activated by p38 MAPK, 
however, MEF2D was phosphorylated to a much lesser extent 35,36. The p38 
phosphorylation of MEF2 transcriptional factors is important in normal development and 
post-natal hypertrophic growth and also in pathological hypertrophy of the heart 37,38. 
The big MAP kinase 1 (BMK1) or ERK5 is the second MAP kinase that directly 
phosphorylates and activates MEF2 (Figure 2) 36,39. ERK5 was found to associate with 
MEF2 through the N-terminal region, which contains the MADS-MEF2 domain and not 
the C-terminal domain, that p38 binds 36. ERK5 phosphorylates MEF2C at Ser387, 
since Ser387 is a conserved residue in MEF2A and MEF2C, but not in MEF2B or 
MEF2D, stimulation of ERK5 only activates MEF2A and MEF2C 36,39. In addition, 
insulin-like growth factor 1 (IGF-1) activates ERK5 in cardiomyocytes, and reduces 
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cardiac apoptosis through MEF2 39. ERK5 also play an important role in cardiac 
hypertrophy in which forced expression of ERK5 in cardiomyocytes induces eccentric 
hypertrophy 40. Multiple calcium-regulated signaling proteins, calcineurin and 
calmodulin-dependent kinase (CaMK) are also involved in regulating MEF2 in 
cardiomyocytes (Figure 2). CaMK directly phosphorylates MEF2D and enhances its 
transcriptional activity 41.  
One of the major MEF2 cardiac cofactors are class II histone deacetylases (HDACs). 
Calmodulin-dependent kinase (CaMK) disrupts MEF2-HDAC complexes by mediating 
nuclear export of the transcriptional repressor, HDACs II, which binds to chaperone 
protein 14-3-3. This event allows MEF2 to associate with histone acetylases (HATs) and 
to activate downstream genes 42. In cardiomyocytes, MEF2 cooperates with NFAT in 
regulation of cardiac hypertrophy 10. In this event, Calcineurin is involved in MEF2 target 
gene regulation, by activation and translocation of NFAT into the nucleus, where it can 
bind to MEF2 43. Calcineurin and CaMK signaling interact through the activation of 
NFAT and MEF2 44, and activation of either calcineurin or CaMK promote cardiac 
hypertrophy 10. 
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Figure 2. Signaling pathways regulating MEF2 in cardiac. MAP kinase cascades 
and the subfamilies include the extracellular regulated kinase 5 (ERK5) and the p38 
MAPK activates MEF2. Calcium dependent signals also activate MEF2 by stimulating 
calcium-dependent kinases, calmodulin Kinase (CaMK) and calcineurin. 
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3. Myocardial remodeling  
          Cardiac diseases such as coronary artery disease, hypertension and heart failure 
are the major causes of death around the world 45. Myocardial remodeling, a step on the 
progression to heart failure, refers to the changes in mass, shape and volume of the 
heart (left ventricular remodeling) in response to a variety of physiologic and 
pathophysiologic stimuli and classified as adaptive and maladaptive. Cardiac 
remodeling occurs due to a variety of pathological conditions in the heart such as 
myocardial infarction, pressure overload and volume overload hypertrophy. The 
underlying molecular and cellular processes leading to cardiac remodeling consist of 
myocyte growth (cardiac hypertrophy), myocyte death, and remodeling of the 
extracellular matrix (ECM) 46,47.  
 
3.1. Cardiac hypertrophy 
          Cardiac hypertrophy refers to the enlargement of the heart due to an increase in 
cardiomyocyte size, resulting from enhanced protein synthesis and assembly of new 
sarcomeres. Cardiomyocyte hypertrophy occurs as a cellular response to increased 
mechanical and neurohumoral stimuli 48,49. Cardiac hypertrophy has two forms; 
physiological hypertrophy and pathological hypertrophy (Figure 3) 49. Physiological 
hypertrophy occurs during normal growth and development in conditions such as 
pregnancy and in response to chronic exercise training. The physiological hypertrophy 
is the proportional increase in the length and width of cardiomyocytes that leads to left 
ventricular hypertrophy and enhanced cardiac performance and is typically not 
associated with cardiac dysfunction, fibrosis, and heart failure 49. Pathological 
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hypertrophy commonly occurs as a result of myocardial valve diseases, myocardial 
infarction and hypertension and it is commonly associated with fibrosis, cardiac 
dysfunction and alterations in cardiac gene expression and heart failure 48. These 
processes lead to the activation of immediate early genes (c-jun, c-fos, c-myc) and 
increased expression of fetal genes such as beta myosin heavy chain (β-MHC), atrial 
natriuretic factor (ANF) and skeletal muscle α-actin 48,50. There are two different 
pathological hypertrophy phenotypes, concentric hypertrophy and eccentric hypertrophy 
(Figure 3) 51. Concentric hypertrophy, occurs when new sarcomeres are added in 
parallel, and is due to pressure overload in conditions such as aortic stenosis or 
hypertension. In contrast, eccentric hypertrophy, refers to the addition of sarcomeres in 
series resulting in longitudinal cell growth due to volume overload in conditions such as 
myocardial infarction 52,53. The ventricular thinning and heart dilation in eccentric 
hypertrophy often leads to dilated cardiomyopathy (DCM) and heart failure 3.  
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Figure 3: Different types of cardiac hypertrophy. The normal heart can lead to 
different types of hypertrophic remodeling depending on the stress. Physiological 
hypertrophy which is associated with exercise and pregnancy and pathological stress 
cardiac hypertrophy. Concentric hypertrophy, caused by chronic pressure overload, 
leads to ventricular wall thickness and eccentric hypertrophy, caused by volume 
overload, leads to thinning of the heart wall and possible dilated cardiomyopathy (DCM). 
This schematic has been adapted from 51. 
 
	   13	  
3.1.1. Signaling pathway in cardiac hypertrophy 
 
          Disease of the adult heart activates a pathological response characterized by 
abnormal growth of cardiac myocytes. This cellular phenotype is the assembly of new 
sarcomeres and activation of a ‘fetal’ set of cardiac genes 48,50. At the molecular level, 
these effects lead to activation of intercellular signaling pathways that ultimately affect 
nuclear factors and the regulation of pathological gene expression programs 54. These 
signaling pathways do not function separately, but they participate in a more organized 
response that generates interdependent and cross-talking networks (Figure 4). Briefly, 
signaling pathways involved in cardiac hypertrophy include G-protein signaling, 
mitogen-activated protein kinase (MAPK), protein kinase A (PKA) and C (PKC) 
signaling, and Ca2+ dependent pathways; calcineurin and calmodulin-dependent kinase 
(CaMK) 46–48,55.  
The most relevant myocardial G-protein coupled receptors (GPCRs) include α- and β-
adrenergic receptors that are coupled to GTP-binding proteins, Gs, Gq/G11, and Gi. 
Stimulation of pathological cardiac hypertrophy agonists, Angiotensin II (AngII), 
Endothelin I (ET-1), and α-adrenergic, activates Gq/11-coupled receptors, which 
activates phospholipase C (PLC), and downstream kinase PKC, and develop concentric 
cardiac hypertrophy 48,50. Forced expression of a dominant-negative Gq in mice can 
almost completely block pathological hypertrophy 48. Stimulation of the β-adrenergic 
receptors (βAR) activates Gαs and adenylate cyclase (AC) activity, accumulation of 
cAMP and subsequent activation of PKA. Acute stimulation of βAR in response to 
epinephrine and norepinephrine is associated with physiological hypertrophy and 
increased contractile function 48. 
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Chronic βAR stimulation results in pathological remodeling and the progression to heart 
failure 56. Forced expression of PKA, the downstream effector of Gαs signaling, in the 
heart results in cardiomyopathy associated with cardiac hypertrophy and fibrosis 57. An 
increase in intracellular Ca2+ concentration in cardiomyocyte activates several Ca2+-
dependent signaling pathways that are involved in the progression of heart failure. 
Calcineurin, a Ca2+/calmodulin (CaM) -activated phosphatase regulating the activity of 
the nuclear factors of activated T cells (NFAT) transcription factor, is involved in 
pathological cardiac hypertrophy and failure 58,59. 
Ca2+/calmodulin-dependent protein kinase II (CaMKII) is also a Ca2+-dependant kinase 
in cardiomyocyte. Activation of CaMKII can phosphorylate and dissociate Class II HDAC 
from binding to transcription factors in the nucleus, and resulting in progression of 
cardiac hypertrophy. CaMKII has also been shown to play a critical role in cardiac 
excitation-contraction coupling in response to β-adrenergic signaling 60. However, 
sustained activation of cytoplasmic CaMKIIδ may phosphorylate proteins involved in 
cardiac apoptosis. It also has been shown that mice deficient in CaMKIIδ in the heart 
are protected from pathological hypertrophy following aortic banding 61. 
ERK family members have also been shown to play a unique role in the signaling 
response to stress stimuli and are downstream effectors of the hypertrophic response 
40,62. P38 MAPK signaling pathways also participate in transducing cardiac hypertrophic 
signals in the heart. Published data existed about p38 MAPK function in cardiac 
hypertrophy, in that either promotion of hypertrophic growth in cultured cardiac 
myocytes, or progression to heart failure in animal models 63,64. 
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Figure 4: Signaling pathways involved in cardiac hypertrophy. Hypertrophic stimuli 
activate intracellular signaling pathways, such as G-proteins, Calcineurin, CaMKII, 
MAP-kinases, and others, in a receptor-dependent manner. The signaling enhancement 
results in phosphorylation, activation, and nuclear translocation of many transcription 
factors that are involved in cardiac hypertrophy gene expressions. This schematic has 
been adapted from 48. 
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3.2. Myocyte death 
3.2.1. Introduction 
          To date, there are two well-recognized signaling pathways for cell death, 
apoptosis and necrosis. Apoptosis and necrosis are considered as two independent 
mechanisms; whereas apoptosis is a genetically controlled process, necrosis is a form 
of accidental death resulting from cellular injury 65.  
Necrosis induces major damage at the cell membrane that results in loss of cellular 
homeostasis, rapid swelling, plasma membrane rupture and release of intracellular 
contents. In contrary, apoptosis is initiated by activation of endogenous proteases that 
results in cell shrinkage, chromatin cleavage, DNA fragmentation, and membrane 
blebbing. Apoptosis process is also involved in formation of membrane enclosed cellular 
organelles called  “apoptotic bodies” that are either phagocytosed by tissue 
macrophages and neighbouring cells or undergoes degradation 65. Both apoptosis and 
necrosis can be seen as a part of the pathogenesis of heart failure that result in loss of 
myocytes due to cell death. 66,67. 
A programmed form of necrosis, necroptosis, is a form of cell death through regulated 
cell signaling pathways 68,69. Whereas, apoptosis is defined as programmed cell death 
that responds to external and internal stimuli, activating separate signaling pathways 
resulting in cell death that does not involve an inflammatory reaction. When apoptosis is 
blocked by the inhibition of caspase activity, necroptosis can act as a backup 
mechanism, 70 ensuring cellular execution due to pathogen infections or cellular 
pathophysiology. Therefore, the induction of necroptotic cell death can be triggered by 
the same stimuli as apoptosis, namely death receptor activation 69. 
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3.2.2. Apoptosis 
 
          Since cardiomyocyte loss is the most important determinant of morbidity and 
mortality after heart pathophysiology, such as ischemia/reperfusion 71, myocardial 
infarction 72 and cardiomyopathies 73, preventing cardiomyocyte loss is important in 
management of heart dilation and failure 74,75. Apoptotic cellular processes are often 
divided into two basic pathways, the “extrinsic” and “intrinsic” pathways (Figure 5). 
In most cases, both pathways involve caspase activation. Caspases are a family of 
cysteine proteases that act as common death effector molecules in cell death pathways 
76. Caspases can activate each other, upon activation; initiator caspases (caspase-2, -8, 
-9 and -10) cleave and activate effector caspases (caspase-3, -6 and -7), which results 
in an increase of caspase activity through a protease cascade to cleave a number of 
different substrates in the cytoplasm or nucleus leading to cell death 76–78.  
In the extrinsic pathway, caspases can be activated at the plasma membrane upon 
binding of extracellular death signal proteins (TNF-α, Fas L, TRAIL) to death receptors 
(receptor pathway). Binding of the ligand to death receptors results in recruitment of the 
death domain adaptor molecules (e.g. TRADD and FADD), form the death-inducing 
complex (DISC), further recruitment and activation of the initiator caspase-8 and the 
downstream effector caspase-3 77.  
The intrinsic pathway (mitochondrial pathway) is primarily activated by cellular stimuli, 
such as hypoxia, ischemia-reperfusion, and oxidative stress. The mitochondrial pathway 
is initiated by the release of apoptotic mediators such as cytochrome c 79, apoptosis 
inducing factor (AIF), Smac (second mitochondria derived activator of caspase) and 
endonuclease G (Endo G) from the mitochondrial intermembrane space. Once 
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cytochrome c is released into the cytosol, it triggers caspase-3 activation through 
formation of the cytochrome c/Apaf-1/caspase-9 “apoptosome” complex. Smac 
indirectly activates caspases, while release of Endo G and AIF from mitochondria 
results in direct or indirect DNA fragmentation 76,77,80,81. A key step in the intrinsic 
pathway is the disturbance of the mitochondrial membrane integrity, which is usually 
regulated by the Bcl-2 protein family. Bcl-2 protein family contain both pro-apoptotic 
(Bax, Bad, Bid, Bik, Bim, Bak, Bnip3) and antiapoptotic (Bcl-2, Bcl-XL, bcl-W) members 
82,83. Activation of caspase-8 may result in cleavage of a pro-apoptotic Bcl-2 family, such 
as Bid, which leads to translocation to mitochondria to release cytochrome c thereby 
initiating the apoptotic pathway 76,77. 
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Figure 5: Programmed cell death, apoptotic pathways. The apoptotic pathways can 
be initiated through different entry sites, at the plasma membrane by death receptor 
ligation (extrinsic pathway) or at the mitochondria (intrinsic pathway). This schematic 
has been adapted from 77. 
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3.2.2.1 Signaling pathways in cardiac apoptosis 
          In the heart, a number of signaling pathways are essential for both pro- and anti-
apoptotic effects in the myocardium. One of these signaling pathways is the MAP 
Kinase family. Mitogen activated protein kinases (MAPKs) are a group of kinases acting 
in succession to regulate cell growth, differentiation, and survival. The MAPK family is 
made up of three major branches: extracellular signal-regulated protein kinase (ERK), c-
Jun N-terminal kinase (JNK), and p38 84. MAPKs could be activated in response to 
multiple agents, such as growth factors, cytokines, and stress. At first, G‐protein 
coupled receptors activate MAPK kinase kinases (MAPKKKs), which target downstream 
MAPK kinases (MAPKKs) leading to subsequent activation of MAPKs. Upon their 
activation, they phosphorylate cytoplasmic, nuclear, and mitochondrial targets to 
regulate a variety of cellular processes including cell death 80. 
In cardiac cells, JNKs were found to play critical roles in the regulation of cell death 
especially via the mitochondrial apoptotic pathway. For instance, in primary 
cardiomyocytes, expression of JNK or MKK4 inhibitory mutants increased ischemia-
reperfusion-induced cardiomyocyte apoptosis, suggesting a protective role for JNK 
signaling 85. On the other hand, inhibition of JNK1 was reported to actually protect 
cardiomyocytes from ischemia-induced apoptosis 86. These findings demonstrate that 
JNKs can have both pro- and anti-apoptotic effects, although more experimental models 
prove induction of the pro-apoptotic pathways 87.  
In the heart, MEK-ERKs have been shown to be part of the insulin-like growth factor-1 
(IGF-1), basic fibroblast growth factor (bFGF), catecholamine and β2-adrenergic 
induced anti-apoptotic pathways 88–90. For instance, ERK1/2 could antagonize apoptosis 
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through association with p90 ribosomal S6 kinase (RSK) by inactivation of the pro-
apoptotic BAD protein and phosphorylation of GATA4 through its association with Bcl-
XL upregulation 87,91. P38 MAPK is thought to play a role in stress-induced apoptosis in 
cardiomyocytes. In contrast, some studies show a protective role of p38 signaling upon 
apoptotic stimulation. For instance, inhibition of p38 MAPK increased norepinephrine-
induced apoptosis in cardiac myocytes 92. On the other hand, in vivo study showed, 
inhibition of p38 promotes protection from ischemia-induced apoptosis 93.  
Similar to the role of p38 MAPK in cardiac hypertrophy, there is also conflicting data 
with regard to p38 role in cardiac apoptosis. Several in vivo studies show the pro-
apoptotic role of p38 in the heart, while in vitro studies support the protective role of p38 
MAPK in cardiomyocytes. 
 
3.2.3. Necroptosis 
           Necroptosis is a programmed cell death pathway similar to unregulated necrotic 
cell death 94. In contrast to apoptosis, the necroptosis signaling pathway is completely 
caspase independent and relies on the stabilization and activation of the kinases RIP1 
Receptor Interacting Protein 1 (RIP1) and Receptor Interacting Protein 3 (RIP3) 95. Both 
kinases are regulated by caspase 8, in which they can be directly cleaved and 
inactivated by caspase 8 96,97. The cellular inhibitors of apoptosis proteins (cIAP) can 
also regulate RIP1. cIAP proteins are responsible for proteasomal degradation of RIP1. 
RIP3 can bind to RIP1 to form a complex called a Necrosome, and within the complex 
RIP3 is phosphorylated and activated by RIP1 98. Active RIP3 can phosphorylate the 
pseudo kinase, Mixed Lingase Kinase Ligase (MLKL) which results in the formation of 
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porous structures, leading to cell and plasma membrane disruption and execution 99.  
The chemical compound necrostatin-1 (Nec-1) inhibits necroptosis without affecting 
apoptosis 100, which shows an independent caspase pathway of necroptosis. Moreover, 
studies in knockout mice have revealed that the regulation of the necroptotic pathway 
plays a direct role in viral infections inflammatory responses 101.  
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4. The role of β-adrenergic receptors in heart 
4.1. Introduction 
           The autonomic (sympathetic) nervous system (ANS) is primarily involved in 
mediating the neuronal and hormonal stress response or fight-or-flight response (ex. 
increased heart rate). Activation of the symapathic nervous system in cardiovascular 
system releases 2 catecholamines, epinephrine (adrenaline) and norepinephrine 
(noradrenaline). Release of norepinephrine by the sympathetic nervous system and 
epinephrine by the adrenal medulla into circulation results in increase heart rate, 
contraction and blood vessel constriction.  
In cells, epinephrine and norepinephrine mediate their effect by binding to adrenergic 
receptors, α1AR subtypes, α2AR and βAR subtypes. 102,103. Regulation of β-adrenergic 
receptors (β-ARs) is important in understanding the mechanism of cardiac performance 
104. β-ARs belong to the superfamily of G-protein coupled receptors. In mammals three 
different subtypes have been distinguished: β1-, β2-, and β3-ARs 105,106. β1-AR is 
predominately expressed in cardiac tissues (control of heart rate and contraction), the 
β2-AR is mainly expressed in the smooth muscle tissue (control of vasodilatory 
responses) and the β3AR is mainly expressed in adipose tissue. In the human heart, 
both β1- and β2-ARs exist and the ratio is 70%: 30% in the atria and 80%: 20% in the 
ventricles with β1-ARs being the dominant receptor 104. When agonists such as 
epinephrine or norepinephrine bind to the receptor, GDP dissociates from the Gαs 
subunits, which then binds GTP. This causes the dissociation of G-protein into Gαs and 
Gβγ. Both β1 and β2ARs exert their physiological effects (increase cardiac contraction) 
by coupling to Gαs and activating adenylate cyclase enzyme, increasing intracellular 
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levels of cyclic adenosine monophosphate (cAMP) and stimulation of cAMP-dependent 
protein kinase A (PKA) 107,108. In addition β2-ARs could also couple to inhibitory Gi 
proteins leading to reduction of adenylyl cyclases activity and subsequently cardiac 
contraction reduction and anti-apoptotic pathway initiation 108,109 (Figure 6). 
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Figure 6: Adrenergic signaling in the heart. Within the heart, the β1-AR, β2-AR and 
induce unique, but overlapping signaling pathways to modulate cardiac contraction, 
survival and growth. This schematic has been adapted from 108.  
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4.2. Cardiac β1-adrenergic receptor function and signal transduction pathway 
            β1-ARs are the dominant receptor subtype in cardiac tissue, as mentioned 
above 104. Under normal conditions, sympathetic activation (primarily by norepinephrine) 
of β1-ARs results in an increase in heart rate (chronotropy) and cardiac contractility 
(inotropy) 105. Acute activation of β1-ARs represent the primary mechanism to increase 
cardiac output (CO) during the sympathetic fight or flight response 105. However, chronic 
stimulation of the β1-AR is cytotoxic in vitro, leading to myocyte death and eccentric 
cardiac remodeling in vivo108. 
The β1-AR binds to Gαs subunits to stimulate the adenylyl cyclase enzyme and 
increase intracellular levels of an important secondary messenger, cAMP. cAMP binds 
to regulatory subunits on PKA, which release and activate the catalytic subunits to 
phosphorylate the downstream effectors that control the cardiac excitation and 
contraction pathway thus regulating chronotropy and inotropy 104 (Figure 7). β1-AR/PKA 
signaling acts on several proteins that are essential for cardiac function: L-type Ca2+ 
channels, ryanodine receptors, phospholamban, and the troponin complex. These 
mechanisms regulate intracellular Ca2+ concentrations, which in turn modulate 
myofilament Ca2+ sensitivity (troponin complex). Generally, increases in intracellular 
Ca2+ concentrations cause binding of the calcium to troponin C and initiate contraction 
(systole) while decreases in intracellular Ca2+ concentrations cause muscle relaxation 
(diastole) 110 (Figure 6) .  
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Figure 7: PKA signaling in the heart. Agonist binding to β-AR activates, via Gs, the 
plasma membrane bound adenylate cyclase (AC), which catalyzes the conversion of 
ATP to cAMP. cAMP activates PKA. Phosphorylation of PKA substrates causes change 
in cardiac inotropy, lusitropy and chronotropy. 
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In cardiomyocytes, the L-type Ca2+ channel (LTCC) is responsible for the conductance 
of the calcium current (ICa), which causes contraction 111. PKA has been shown to be 
involved in phosphorylation of LTCC and activation of ICa 112. Ryanodine receptors 
(RyRs) located on the sarcoplasmic reticulum are important in cardiac excitation-
contraction coupling. The increase in intracellular calcium triggers further calcium 
release from the sarcoplasmic reticulum through the RyRs. β-AR/cAMP/PKA pathway 
play an indirect regulatory role on the function of RyRs, in which PKA-mediated 
phosphorylation of RyRs activates L-type Ca2+ channel and increase the release of 
sarcoplasmic Ca2+ through RyRs 113. The regulation of RyRs is important for producing 
acute increases in the heart’s pumping power 113. PKA-mediated hyper-phosphorylation 
of RyRs might increase cytosolic Ca2+ levels and lead to the pathogenesis of heart 
failure 114. An important target of PKA is phopholamban (PLB), a sarcoplasmic reticulum 
membrane protein that controls the sarcoplasmic reticulum Ca2+ uptake by inhibiting 
SERCA (The sarcoplasmic/endoplasmic reticulum Ca2+ ATPase). During rest, PLB is in 
a dephosphorylated state and inhibits SERCA. Activation of β-ARs leads to PKA-
mediated phosphorylation of PLB, which increases sarcoplasmic reticulum Ca2+ uptake 
from cytoplasm. The overall results are important for cardiomyocyte relaxation (positive 
lusitropy). Further PKA targets are myosin-binding protein C and troponin, which reduce 
Ca2+ sensitivity of myofilaments. Although β1-AR stimulation is important in 
physiological excitation contraction coupling within the heart, chronic stimulation and 
acute over-stimulation can cause damage to myocardial tissue. Pharmacological 
studies have reported that stimulation of β1-AR leads to cardiac apoptosis 115. The 
mechanisms of cardiac apoptosis appear to be both PKA-dependent and independent. 
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Some studies show that β1-AR mediated apoptosis was blocked by the PKA inhibitor 
(H89), and PKA activators (forskolin) induced apoptosis 90. On the other hand, other 
studies demonstrated that β1-AR activation of CaMKII causes the release of 
mitochondrial cytochrome C and induces cardiac apoptosis in a PKA-independent 
pathway 116. In addition, inhibition of PKA activity showed prevention of CaMKII 
activation and induction of cardiac apoptosis. This demonstrates the co-dependence of 
these two pathways117.  
 
4.3. β-adrenergic blockers and cardiac diseases  
          Since the Nobel Prize winning development of β-adrenergic antagonists (β-
blockers) for the treatment of angina and cardiac arrhythmias by Sir James Black 118,119, 
this class of drugs has proved to be one of the most impactful in terms of contributions 
to pharmacology and medicine.  
β-blockers are a class of drugs that are used to treat a wide range of cardiovascular 
diseases (hypertension, coronary artery disease, myocardial infarction (MI), and 
congestive heart failure as well as various non-cardiovascular diseases (glaucoma, 
migraine and anxiety) 120,121. β-blockers block the effect of catecholamines (e.g. 
norepinephrine and epinephrine) on β1 and β2-subtypes of cardiac adrenergic 
receptors in patients with heart failure, and reduce heart rate and blood pressure by 
dilating blood vessels. Therefore, the enhanced sympathetic activation of the heart is 
inversely correlated with survival by β-blockers treatment, indicating one compelling 
reason why β-blockers are useful in heart disease. 
β-blockers have been subsequently developed since the first generation of non-
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selective (β1 +β2) β-blockers (propranolol), to the more cardio-selective β1-specific 
antagonists (atenolol, metoprolol, and bisoprolol). Selective β-blockers mainly act on the 
heart and do not affect airway passages. β-blockers that cross-react with β2-ARs such 
as propranolol can inhibit β2-AR mediated vasodilation and potentially shift the balance 
towards vasoconstriction, which leads to a reduction in tissue perfusion 122. 
β-blockers protect the heart by balancing myocardial oxygen supply-demand and 
controlling heart rate 123. Through this mechanism, β-blocker therapy has been used for 
patients after myocardial infarction (MI), as it is associated with a substantial reduction 
in the risk of re-infarction and mortality 120. A randomized controlled trial evaluated 
treatment with atenolol (β1 selective blockade) in patients within hours after the MI, and 
found a significant decrease in mortality compared to no treatment. This shows clear 
benefits of early β-blocker therapy within 24 hours of MI symptoms 124–126. 
As mentioned above, a healthy human heart contains 80% β1-ARs and 20% of the β2-
ARs. In heart failure, the number of β1-AR decreases such that there are 60% β1 and 
40% of the β2. There is also evidence that long-term activation of β1-ARs in mice is 
more toxic to the myocardium than activation of β2-ARs. Also, transgenic mice 
overexpressing β1-ARs develop cardiac failure and die, whereas β2-ARs 
overexpression is more tolerable. In humans, activation of β1-ARs is associated with an 
increase in mortality and they are restricted to short-term maintenance of cardiac output 
in intensive and coronary care units. The beneficial use of β-blocker treatment for heart 
failure was questionable at the beginning, but subsequent clinical trials proved that β-
blockers are effective in reducing mortality in patients with heart disease 56,114. 
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CHAPTER 2: Statement of Purpose  
         The enhanced sympathetic drive due to binding of catecholamines, 
norepinephrine and epinephrine, to the β1 and β2-subtypes of cardiac adrenergic 
receptors in the heart is one factor contributing to the progression to heart failure. 
However, this adrenergic stimulus is also important in controlling cardiac inotropic, 
chronotropic and lusitropic physiological parameters.  
There is a lack of information regarding how acute and chronic β-adrenergic signaling 
affects cardiac gene expression. Also, evidence indicates that regulation of the 
expression of a transcriptional regulatory protein can exert considerable control over the 
gene expression profile. MEF2 proteins are important transcription factors involved in 
cardiac gene expression in both physiological and pathological adaption of the heart. 
Therefore the overall purpose of this work was to identify an important link between the 
pharmacological blockade of β-adrenergic signaling in the heart and cardiac gene 
expression, particularly with respect to MEF2.  We assessed whether this link is 
involved at an acute level, protection of cardiomyocytes from apoptosis in the early 
events post myocardial infarction and also in chronic conditions, in resistance to longer-
term changes in cardiac gene expression leading to cardiac failure. This purpose was 
achieved experimentally through addressing the following specific objectives outlined 
below: 
1) To determine how MEF2 activity is regulated during acute β-adrenergic blockade and 
determine whether this is protective against cardiomyocyte death.  
2) To characterize changes in the cardiac gene transcriptome network and MEF2 
activity during heart failure with and without β-adrenergic blockade. 
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3) To begin to assess the potential role of some of these differentially expressed genes 
in cardiomyocyte apoptosis and hypertrophy. 
Considering human heart disease and therapy, this work would contribute in 
understanding the molecular events essential in how β-adrenergic receptor blockers 
have positive effects on heart pathology. 
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CHAPTER 3 
 
 
PRO-SURVIVAL FUNCTION OF MEF2 IN CARDIOMYOCYTES IS ENHANCED BY  
β-BLOCKERS χ 
 
 
 
Summary  
β1-Adrenergic receptor (β1-AR) stimulation increases apoptosis in cardiomyocytes 
through activation of cAMP/protein kinase A (PKA) signaling. The myocyte enhancer 
factor 2 (MEF2) proteins function as important regulators of myocardial gene 
expression. Previously, we reported that PKA signaling directly represses MEF2 activity. 
We determined whether (a) MEF2 has a pro-survival function in cardiomyocytes, and 
(b) whether β-adrenergic/PKA signaling modulates MEF2 function in cardiomyocytes. 
Initially, we observed that siRNA-mediated gene silencing of MEF2 induces 
cardiomyocyte apoptosis as indicated by flow cytometry. β1-AR activation by 
isoproterenol represses MEF2 activity and promotes apoptosis in cultured neonatal 
cardiomyocytes. Importantly, β1-AR mediated apoptosis was abrogated in 
cardiomyocytes expressing a PKA-resistant form of MEF2D (S121/190A). We also 
observed that a β1-blocker, Atenolol, antagonizes isoproterenol-induced apoptosis while 
concomitantly enhancing MEF2 transcriptional activity. β-AR stimulation modulated 
MEF2 cellular localization in cardiomyocytes and this effect was reversed by β-blocker 
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treatment. Furthermore, Kruppel-like factor 6, a MEF2 target gene in the heart, functions 
as a downstream pro-survival factor in cardiomyocytes. Collectively, these data indicate 
that (a) MEF2 has an important pro-survival role in cardiomyocytes, and (b) β-
adrenergic signaling antagonizes the pro-survival function of MEF2 in cardiomyocytes 
and β-blockers promote it. These observations have important clinical implications that 
may contribute to novel strategies for preventing cardiomyocyte apoptosis associated 
with heart pathology. 
 
Introduction 
Morbidity and mortality associated with heart disease remain a prevalent worldwide 
health concern 127. In the diseased heart, the lack of capacity for tissue regeneration 
after injury contributes to diminished cardiac function and heart health. At the cellular 
level, irreversible loss of cardiac myocytes due to programmed cell death contributes to 
pathological ventricular remodeling and progression to heart failure 115,128. Therefore, 
understanding the molecular genetic pathways that induce and also prevent myocardial 
cell apoptosis has potentially profound implications for understanding heart pathology 
and also therapeutic interventions for heart disease 128,129.  
β-Adrenergic receptor (β-AR) antagonists, or β-blockers, are a class of highly effective 
front-line drugs for heart disease that, at the molecular level, block norepinephrine and 
epinephrine from binding to the β-ARs. β-Blockers primarily block β1 and β2 receptors 
and their efficacy in the heart is related to their capacity to influence both chronotropy 
and inotropy by reducing both heart rate and the force of myocardial contraction. Thus, 
this reduction in heart work by β-blockers has been effectively used to ameliorate 
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hypertrophy and cardiac dilation leading to heart failure 130. Interestingly, one reported 
benefit of chronic β-blocker treatment is in reducing myocyte death in patients with heart 
failure 114,131. Although activation of β1-AR, the predominant β-AR in the heart, has an 
important role in the regulation of normal heart function, prolonged activation of the β-
adrenergic system in human heart disease or in experimental model systems results in 
dilated myopathy, cardiac fibrosis, cardiac myocyte apoptosis and heart failure 121,132. 
Previous studies have suggested that the cAMP/PKA pathway downstream of β1-AR 
induces cardiac myocyte apoptosis which is supressed by β-blocker therapy 128,133. 
However, the mechanism by which prolonged β-adrenergic activation compromises the 
survival of cardiac myocytes has not previously been elucidated. Recently, we have 
reported that one of the myocyte enhancer factor 2 (MEF2) proteins (MEF2D), which is 
a key transcriptional regulator of cardiac gene expression, is directly targeted by PKA 
signaling 134. Although the role of MEF2 proteins in cardiovascular development and 
post-natal growth and hypertrophy has been extensively documented, 135–138 there has 
previously been no clear link between MEF2 and cell survival pathways in the heart. 
MEF2s belong to the MADS (MCM1, agamous, deficiens, serum response factor) 
superfamily of sequence specific DNA-binding transcription factors. The N terminus of 
MEF2 proteins is highly conserved among all family members and consists of a 58-
amino acid MADS domain and an immediately adjacent 28-amino acid MEF2 domain. 
These two domains collectively mediate dimerization, co-factor interactions and DNA 
binding to the consensus DNA sequence (C/T)TA(A/T)4TA(G/A) found in the regulatory 
region of most cardiac-specific genes 139. The two major isoforms of MEF2 in the adult 
heart are MEF2A and MEF2D, which form heterodimers 140.	  Although a pro-survival role 
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of MEF2 has not been reported in striated muscle cells, a potent role of MEF2 in 
neuronal survival pathways has indeed been reported 16. Moreover, we recently 
documented that PKA activation leads to abrogation of MEF2 activity and pro-survival 
mechanisms in primary hippocampal neurons 17. This effect is mediated by a direct 
repressive effect of PKA phosphorylation of MEF2D at serines 121 and 190 leading to 
inhibition of its transactivation properties 134. In view of the potent role of both MEF2 and 
β-adrenergic signaling in the molecular control of heart structure and function, we 
explored a possible connection between β-adrenergic signaling and MEF2 in 
cardiomyocyte survival. Here, we report, for the first time, that MEF2 has a pivotal 
prosurvival role in cardiomyocytes. Moreover, we observed that β-adrenergic activation 
directly antagonizes this MEF2 pro-survival role and β-adrenergic blockade restores this 
function, promoting cardiomyocyte survival. In addition, we document that the Kruppel-
like factor 6 (KLF6) is an important downstream target of MEF2 in the cardiomyocyte 
survival pathway. These observations have important clinical implications for heart 
disease, firstly establishing that MEF2 has a key pro-survival role in the heart and 
secondly, documenting that β-adrenergic signaling intersects with this MEF2 survival 
pathway establishing a therapeutic node for intervention in cardiomyocyte apoptosis. 
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Results 
MEF2 functions as a pro-survival factor in cardiac myocytes  
MEF2 has previously been implicated in cell survival in primary embryonal hippocampal 
neurons 17 and in cerebellar granular neurons141. Although it is well documented that 
MEF2 functions as a key regulator of cardiac myocyte differentiation, 30,142 its role, as a 
possible survival factor has not been proven. Recently, we have identified some 
potentially novel aspects of MEF2 function in skeletal and cardiac muscle using high 
throughput genomic technologies such as ChIP-Exo and RNA-seq which based on 
gene ontology analysis, suggest a wider role for MEF2A than just cellular differentiation 
143. Interestingly, MEF2A-null mice exhibit an increase in cell mortality in the post-natal 
period 30. Therefore, we sought to rigorously address the question of whether MEF2 has 
a direct role in cardiomyocyte survival. Initially, we used siRNA mediated gene silencing 
to downregulate MEF2A expression in primary cardiac myocytes followed by flow 
cytometry analysis to detect apoptotic cells. The efficacy of MEF2A silencing was tested 
by western blot analysis of primary cardiomyocytes that were transfected with two 
independent MEF2A siRNAs and a control scrambled siRNA (scRNA). As shown in 
Figure 8b, a robust reduction of MEF2A protein level was observed in cells expressing 
siMEF2A in contrast to cells expressing scRNA. To examine whether MEF2A silencing 
resulted in cardiomyocyte apoptosis, a combination of PI and annexin V-FITC 
fluorescence was used to determine necrosis and apoptosis by flow cytometry. An 
increase in the percentage of apoptotic cells with cardiomyocyte MEF2A silencing was 
observed as indicated in the lower right quadrant of the density plot (high Annexin V, 
low PI). Depletion of MEF2A enhanced the levels of cardiomyocyte apoptosis (27.67 
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and 25.70%) compared with the scRNA control condition (7.03%; Figure 8a). These 
data indicate that MEF2A has a pro-survival role in cardiomyocytes. Next, we 
interrogated the role of MEF2A depletion in cardiomyocyte gene expression in RNA-
seq. A full description and bioinformatics analysis of these RNA-seq data will be 
published elsewhere (Hashemi and Wales, in preparation). However, with respect to 
apoptosis, we observed a significant enrichment of the gene ontology term, ‘positive 
regulation of apoptotic process’ in the data set. Using GeneMania, 144,145 the 20 genes 
with the lowest P-value were plotted to demonstrate the potential role MEF2A may have 
in regulating the expression of apoptosis-related genes. Several key apoptotic and 
tumor suppressor genes are upregulated including Bcl2l14, 146, Bnip3, 147,148 Rassf6  149 
and Ddit3 150 (Figure 8c). 
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Figure 8. MEF2A knockdown induces apoptosis in cardiomyocytes. (a) Annexin V 
detection is upregulated in MEF2A-depleted cardiomyocytes. Primary cardiomyocytes 
were transfected with two independent MEF2A siRNAs or a control scRNA. Cells were 
stained with annexin V-FITC and PI using annexin V-FITC apoptosis detection kit 48 h 
after transfection. Apoptosis was measured using flow cytometry analysis (FACS 
analyzer). (b) siRNA-mediated gene silencing reduces MEF2A protein. Equal amounts 
of total protein were used for western blot analysis. The levels of the indicated proteins 
were assessed by a standard immunoblotting technique using specific primary 
antibodies for each as indicated. (c) RNA-seq analysis of MEF2A knockdown in 
cardiomyocytes. siMEF2A#1 or a control scRNA were transfected in cardiomyocytes in 
duplicate and prepared for RNA-seq analysis. The gene ontology (GO) term, positive 
regulation of apoptotic process, was observed. The 20 genes within this category with 
the lowest P-value are shown in a network created by the program GeneMania. Green 
and red nodes indicate down- and upregulated genes, respectively, whereas 
connections between nodes are as follows: purple, co-expression; orange, predicted; 
blue, co-localization; green, shared protein domains; gray, other. 
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Acute β1-AR signaling represses MEF2 activity leading to cardiomyocyte 
apoptosis  
It has been documented that apoptotic cell death can be induced by β1-AR activation 
and is cAMP/PKA dependent 115,128. In Skeletal muscle, we have previously shown that 
cAMP/PKA signaling is a potent repressor of MEF2D function and myogenic 
differentiation 134. As the β-adrenergic system is such an important regulator of 
physiological and pathological heart function, we sought to determine whether acute β1-
AR activation might impinge on the survival function of MEF2. Initially, we assessed 
activation of β1-AR-mediated apoptosis in primary cardiomyocytes by flow cytometry. 
Estimation of necrosis and apoptosis were again determined by a combination of PI and 
annexin V-FITC fluorescence, respectively. Substantial increases in apoptotic cells 
(cells appearing in the lower right quadrant of the density plot) were observed with 
isoproterenol (Iso; 10 µM) treatment (30.31%) when compared with control cells 
(10.77%; Figure 9a). To determine whether the mechanism leading to apoptosis is 
through cAMP–PKA pathway, we used a well-known pharmacological inhibitor of PKA, 
H89 (20 µM) before treatment with Iso (10 µM). Subsequently, reporter gene analysis 
demonstrated a reduction of MEF2 activity in Iso-treated cells, which was reversed by 
H89 treatment (Figure 9b). MEF2A and MEF2D are the two major isoforms of MEF2 in 
post-natal hearts that form heterodimers 140. PKA was found to directly phosphorylate 
MEF2D in our previous work,134 which also showed that this repressive effect was 
transdominant over MEF2A activity when MEF2A heterodimerized with MEF2D, as is 
the case in cardiomyocytes. PKA directly phosphorylates S121 and S190 on MEF2D 
and these sites were sufficient for repressive effects on skeletal muscle differentiation in 
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response to cAMP signaling 134. To investigate this further, we determined whether a 
PKA-resistant MEF2D mutation (MEF2D S121/190A) could ameliorate β1-AR-PKA-
mediated apoptosis in response to Iso. We noted a decrease in apoptotic 
cardiomyocytes when S121/190A was overexpressed with Iso (10 µM; 4.14%), 
compared with Iso alone (8.88%) in cardiomyocytes (Figure 9c). Conversely, 
phophomimic form of MEF2D (S121/190D) did not rescue Iso-induced cardiomyocyte 
cell death (Figure 9c). These results demonstrate that a PKA-resistant MEF2D 
(S121/190A) protects cardiomyocytes from Iso-induced apoptosis. 
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Figure 9. Activation of β1-AR induces cardiomyocytes apoptosis through the PKA 
pathway. (a) Primary cardiomyocytes were treated with Iso (10 µM) for 48 h and then 
stained with annexin V-FITC and PI using annexin V-FITC apoptosis detection kit. 
Apoptosis was measured using flow cytometry analysis. (b) Cardiomyocytes were 
transfected with 4xMEF2-Luc reporter gene and treated with Iso (10 µM) alone or in 
combination with PKA inhibitor (H89, 20 µM). Luciferase activity was assessed using 
the respective reporter gene and normalized to β-galactosidase (β-gal) activity. Data are 
the mean±S.E. The quantification data is between the same batch with n=3, **P≤0.01 
comparing Iso with control, ##P≤0.01 comparing H89/Iso to Iso. (c) PKA-resistant 
MEF2D rescues cardiomyocytes. Primary cardiomyocytes were transfected with empty 
vector or mutated forms of MEF2D S121/190A (MEF2D (A), neutralizing) and 
S121/190D (MEF2D (D), phospho-mimetic) and then treated with with Iso (10 µM). Cells 
were prepared for FACS analysis as in a. n =3, **P ≤0.01 Iso versus control, #P ≤0.05 
Iso+MEF2D (A) versus Iso. 
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A β1-selective adrenergic receptor blocker (Atenolol) enhances MEF2 
transcriptional activity in primary cardiomyocytes  
Given our data showing that β1-AR agonists activate PKA and induce apoptosis in 
cardiomyocytes, at least in part, by blocking the pro-survival role of MEF2A/D 
heterodimers, we next addressed the effects of β-blockers on MEF2 activity. As β-
blocker therapy effectively is a first line treatment for most heart pathology, 115 we 
hypothesized that its impact on MEF2-mediated pro-survival, in conjunction with the 
well-known effects of β-blockers on cardiac contractility could contribute to the 
protective effects of pharmacological blockade of β1-AR in the heart. To test this 
hypothesis, we initially used an in vivo model a MEF2-LacZ sensor mouse 151–153 were 
treated with either β-blockers (Atenolol	  (Ate) 50 mg/kg per day) or solvent (water) for 48 
h. The heart tissue was then stained with X-Gal (5-bromo-4-chloro-3-indolyl-β-d-
galactopyranoside) and visualized for MEF2 activity. The data indicated a substantial 
enhancement of MEF2 activity in relatively acute β-blocker treatment in the hearts, as 
illustrated by X-Gal staining (Figure 10a). To document these effects in a more 
controlled manner, primary cardiomyocytes in vitro were transfected with a 4xMEF2-
Luciferase construct (a synthetic reporter gene containing four copies of the MEF2 cis-
element in tandem) and were treated with Ate (10 µM) alone and in combination with Iso 
(10 µM) for 48 h before determination of MEF2 transcriptional activity. These data 
illustrate that Ate enhances MEF2 transcriptional activity (Figure 10b). To further 
corroborate this, the effect of β-blockers on a natural heart promoter (atrial natriuretic 
factor—ANF), a previously well-characterized MEF2 target gene, 154 154 was analyzed. 
Standard reporter gene analysis was performed using the ANF-Luc reporter gene with 
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Ate (10 µM) and Iso (10 µM) treatment. These experiments revealed that Iso (10 µM) 
treatment repressed Ate-Luc activity and this effect was abrogated with Ate, consistent 
with the idea that β-agonists repress ANF promoter activity through the MEF2 cis-
element (Figure 10c, left panel). This was confirmed by utilizing an ANF-Luc reporter 
gene construct in which the MEF2 site was mutated by substitution of the A/T rich core 
of the MEF2 site with a GGG tri-nucleotide, which completely abrogates MEF2 binding 
(ANF-Luc ΔMEF2) (Figure 10c, right panel). Collectively, these data indicate that 
cardiomyocyte MEF2 activity on synthetic and natural promoters is repressed by Iso 
treatment and de-repressed by Ate treatment. These data demonstrate a potent level of 
control of cardiomyocyte MEF2 activity by β-adrenergic signaling. 
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Figure 10. Ate enhances MEF2 transcriptional activity in cardiomyoytes. (a) 
Animal treatment with Ate in vivo. MEF2-LacZ transgenic mice were fed daily with Ate 
(50 mg/Kg per day) or water for 48 h. After treatment, mice were killed and hearts were 
fixed with 2% paraformaldehyde in PBS for 30 min. The samples were then incubated 
with X-Gal solution overnight and visualized for MEF2 activity. The dark blue stain 
indicates MEF2 activity. (b) Cardiomyocytes were transfected with 4xMEF2-Luc reporter 
gene and treated with Iso (10 µM), Ate (10 µM) alone or in combination. Luciferase 
activity was assessed using the respective reporter gene and normalized to β-
galactosidase. Data are the mean±S.E. n=3, ****P≤ 0.0001 comparing Iso to control, 
**P≤0.01 comparing Ate/Iso to Iso, *P ≤0.05 comparing Ate to control. (c) Ate enhances 
transactivation of the ANF promoter through MEF2. The effect of Iso (10 µM), Ate (10 
µM) alone and in combination was assessed on ANF-Luc or an analog with the MEF2 
site mutated (ANF-Luc ΔMEF2) in cardiomyocytes. Data are the mean±S.E. n=3, ****P 
≤0.0001 Iso versus control, ##P ≤0.01 Ate/Iso versus Iso, *P≤0.05 Ate versus control. 
 
 
 
 
 
 
 
 
	   49	  
β-AR activation modulates MEF2D cellular localization in neonatal 
cardiomyocytes 
In attempting to determine the mechanism by which MEF2 activity is repressed by β-
adrenergic signaling, we determined the subcellular localization of MEF2D in 
cardiomyocytes that were treated with Iso (10 µM) alone and in combination with β-
blockade Ate (10 µM) and ICI118551 (1 µM) using Immunofluorescence analysis. As 
shown in Figure 11 (top panel), MEF2D is mainly localized in the nucleus in solvent 
treated cells. However, we observed that in Iso-treated cells, MEF2D is mostly localized 
in the cytosol Figure 11 (middle panel). We further documented that with β-blocker 
treatment, MEF2D localization in the nucleus was restored Figure 11 (bottom panel). 
We observed a similar disruption of cellular localization patterns of MEF2A in 
cardiomyocytes treated with Iso alone and in combination with β-blockers (Figure S2). 
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Figure 11. β-AR activation modulates cellular localization of MEF2D in 
cardiomyocytes. Primary cardiomyocytes were treated with solvent or Iso (10 µM) 
alone and in combination with β-blockers Ate (10 µM) and ICI118551 (1 µM). After 
treatment, cells were fixed with 4% paraformaldehyde and immunofluorescence 
analysis was performed using a primary antibody to MEF2D (red). DAPI (4,6-diamidino-
2-phenylindole) was used to identify nuclei (blue). The merged pictures demonstrate 
localization of MEF2D (red) in respect to Iso (10 µM), β-blockers Ate (10 µM) and 
ICI118551 (1 µM) treatment, counterstained with DAPI. Scale bars, 20 µm. 
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KLF6 functions downstream of MEF2 as a pro-survival factor in cardiomyocytes 
We previously observed that KLF6 is a key MEF2D target gene in primary hippocampal 
neurons, 17 and therefore sought to determine whether KLF6 might also function in 
cardiomyocytes. Endogenous expression of KLF6 was initially confirmed in primary 
neonatal cardiomyocytes and HL1 cells using western blot analysis (Figure 12a). 
Immunofluorescence analysis indicated expression of KLF6 in MEF2D positive primary 
cardiomyocytes. The data also indicate nuclear localization of both MEF2D (green) and 
KLF6 (red) in cardiomyocytes (Figure 12b). We also observed a similar cellular 
localization pattern of KLF6 and MEF2D in HL1 cells (Figure S3). Firstly, we assessed 
MEF2-dependent regulation of the KLF6 promoter in cardiomyocytes. To do this we 
used a number of KLF6 promoter reporter gene constructs containing different 
fragments of the KLF6 promoter, pROM6 (contains MEF2 cis-element), pROM3 (which 
has no MEF2 site), mut.pROM6 (contains MEF2-binding site mutation) and pGL3- basic 
empty vector which was used as a control (schematic in Figure 12c, lower panel). As 
shown in Figure 12c (upper panel), endogenous MEF2-induced pROM6 reporter 
transcriptional activity in contrast to pROM3, which lacks the MEF2-binding site. 
Furthermore endogenous MEF2 did not induce KLF6 reporter transcriptional activity 
when the MEF2 site is mutated, indicating that MEF2 is a transcriptional regulator of the 
KLF6 promoter. To further test if KLF6 is a potential MEF2 target gene in cardiac 
myocytes, we used siRNA targeting to reduce MEF2D and -A expression and then 
assessed KLF6 protein expression. Cardiomyocytes were transfected with three 
independent MEF2D siRNAs and scRNA. MEF2D silencing resulted in a concomitant 
repression of KLF6 protein expression (Figure 12d, left upper panel) corresponding with 
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a decrease in KLF6 promoter activation (pROM6; Figure 12d, lower panel). In addition, 
the reduction of KLF6 protein level was also observed in cells expressing siMEF2A in 
contrast to cells expressing the scRNA control (Figure 12d, right panel). 
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Figure 12. MEF2 regulates KLF6 expression in cardiomyocytes (a) KLF6 protein 
expressed in cardiomyocytes. Cell lysates of primary cardiomyocytes and HL1 cells 
and C2C12 (as control) were prepared and equal amounts of total protein were used for 
western blot analysis. The levels of the indicated proteins were assessed by a standard 
immunoblotting technique using specific primary antibodies for each as indicated. (b) 
Cellular localization of MEF2D and KLF6 in cardiomyocytes. Primary cardiomyocytes 
were fixed with 4% paraformaldehyde. Double immunofluorescence labeling 
demonstrating KLF6 (red) and MEF2D (green) and DAPI (4,6-diamidino-2-phenylindole) 
was used to identify nuclei (blue). (c) MEF2-dependant induction of the KLF6 promoter 
in cardiomyocytes. Schematic illustrations of KLF6 reporter gene constructs used in 
reporter assays are indicated in the lower panel. All KLF6 promoter constructs were 
cloned into the pGL3-basic reporter vector (pGL3-KLF6-Luc). Primary cardiomyocytes 
were transfected with various constructs of the KLF6 promoter, pROM6, pROM3 and 
pROM6 with the MEF2 site mutated. Cell extracts were prepared and MEF2-mediated 
transcriptional activity was determined by luciferase and β-gal assays. n =3, ***P≤0.001 
pROM6 versus pGL3. (d) KLF6 expression is reduced in MEF2 depleted 
cardiomyocytes. Primary cardiomyocytes were transfected with three independent 
MEF2D siRNAs (left panel) or two independent MEF2A siRNAs (right panel). Forty-eight 
hours after transfection equal amounts of total protein were used for western blot 
analysis. The levels of the indicated proteins were assessed by a standard 
immunoblotting technique using specific primary antibodies for each as indicated. KLF6 
reporter gene expression is reduced in MEF2D depleted cells. Luciferase activity was 
assessed using KLF6 promoter driving luciferase (pROM6-Luc) and normalized to β-
galactosidase. Data are the mean ±S.E. (n=3), **P ≤0.01, *P≤0.05 comparing to control. 
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KLF6 protects cardiomyocytes in β1-AR–PKA pathway 
In an attempt to assess the functional role of KLF6 in cardiomyocytes, we silenced its 
expression using siRNA technology. Neonatal cardiomyocytes were transfected with 
three independent KLF6-siRNAs or scRNA and cardiomyocyte apoptosis was measured 
by flow cytometry analysis as described above (Figure 13a, left panel). Quantitative 
analysis shows depletion of KLF6 expression resulted in 2- to 3-fold increase in 
cardiomyocyte apoptosis compared with the control condition (Figure 13a, right	   upper 
panel). Reduction of KLF6 protein was observed in cells expressing siKLF6 in contrast 
to the scRNA (Figure 13b). Interestingly, we also observed that exogenous 
overexpression of KLF6 can reduce the amount of cell death provoked by Iso treatment 
(Figure 13c). To examine whether the expression of KLF6 is targeted when MEF2 
activity is repressed by β1-AR–PKA signaling, cardiomyocytes were treated with Iso (10 
µM) followed by western blot analysis of KLF6. As shown in Figure 13d, KLF6 protein 
expression level was suppressed by activation of β1-AR–PKA signaling. These data 
indicate that reduction in KLF6 expression by β1-AR activation occurs through MEF2 
inhibition. Collectively, these data summarized in Figure 13, suggest that KLF6 
functions downstream of MEF2 in a cardiomyocyte survival pathway. 
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Figure 13. Role of KLF6 in cardiomyocyte survival. (a) siRNA-mediated depletion of 
KLF6 expression enhances apoptosis in primary cardiomyoytes. Primary 
cardiomyocytes were transfected with three independent KLF6 siRNAs and a control 
scRNA. Seventy-two hours after transfection, cells were stained with annexin V-FITC 
and PI using annexin V-FITC apoptosis detection kit. Cardiomyocytes apoptosis was 
measured using flow cytometry analysis (FACS analyzer). Changes in the number of 
apoptotic cells is indicated in a bar graph (left panel). n=3, **P ≤0.01,*P≤0.05 comparing 
to control. (b) Equal amounts of total protein were used for western blot analysis to 
validate KLF6 knockdown. The levels of the indicated proteins were assessed by a 
standard immunoblotting technique using specific primary antibodies for each as 
indicated. (c) Exogenous KLF6 expression rescues cardiomyocytes apoptosis. Primary 
cardiomyocytes were transfected with KLF6 expression vector or a control vector and 
then treated with Iso (10 µM). Cells were then prepared for FACS analysis. (d) 
Activation of β1-AR suppresses KLF6 protein expression. Primary cardiomyocytes were 
treated with Iso (10 µM) or solvent. Cells were prepared for western blot analysis as in 
b. 
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Discussion 
Here, we present several lines of evidence documenting that MEF2 activity has an anti-
apoptotic, pro-survival role in cardiac myocytes. Moreover, this pro-survival activity is 
antagonized by β-adrenergic signaling and, importantly, enhanced by β-adrenergic 
blockade (Figure 14). In view of the profound effects of myocyte loss in heart pathology, 
it is perhaps   appropriate   to consider possible contexts occurring in the cardiovascular 
system in which these observations have potentially important implications. One 
prominent context exists immediately after myocardial infarction, when the survival of 
cardiomyocytes in the myocardium is known to be severely compromised and also 
MEF2 activity is repressed by hyperactivation of β-adrenergic signaling and subsequent 
PKA-mediated phosphorylation. Our data indicate that β-blockade immediately post 
myocardial infarction could minimize cell death by promoting the cell survival 
mechanisms invoked by MEF2 and its downstream effectors. There are other conditions 
of acute hyper-adrenergic activation in humans, apart from myocardial infarctions, that 
have been linked with heart pathology 155. In patients with stress cardiomyopathy a link 
between myocyte death and pronounced acute β-adrenergic activation has been 
postulated 155. Certainly it is clear that   one   seminal   feature   of progressive   heart   
failure is an elevation in catecholamine levels that results in myocyte death and 
concomitant hypertrophy in surviving cells, ultimately contributing to a worsening   of left 
ventricular function 156–158. 
Indeed, the general cardio-toxicity of high levels of catecholamine in the   heart   and   
more   specifically the   exact role of catecholamine mediated myocyte death is, to date, 
not well understood, although it has been reported that chronic hyper-activation of β-
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adrenoreceptors leads to a PKA-mediated phosphorylation of the Ryanodine receptor   
that results in calcium leakage from the sarcoplasmic reticulum, possibly invoking cell 
death mechanisms 159. Despite the link between cardiac pathology and elevated 
catecholamine levels documented in multiple, 155–159 our knowledge  of the mechanisms  
leading to cell death  in these contexts  is still incomplete. On the basis of our 
observations, we propose that acute β-adrenergic stimulation mediates inactivation of 
the pro-survival function of MEF2 in cardiac myocytes, thereby contributing to myocyte 
cell death and left ventricular dysfunction in a variety of pathologies ranging from 
myocardial infarction to stress induced cardiomyopathy. Moreover, acute β-adrenergic 
blockade restores MEF2 activity thus facilitating cardiac myocyte survival. 
We report here that the expression of a substantial number of apoptotic network related 
genes is affected by experimental manipulation of MEF2 activity (Figure 8). For 
example, in our experiments several key apoptotic and tumor-suppressor genes are 
upregulated in response to MEF2A suppression by siRNA technology, suggesting that 
MEF2 ordinarily represses these pro-apoptotic genes, including   Bcl2l14,146 Bnip3 
(Bcl2-  and 19KD-interacting   protein-3), 147,148 Rassf6 149 and  Ddit4 (DNA damage-
inducible transcript 4). Bnip3-mediated cardiomyocyte apoptosis contributes to post-
infarction left ventricular remodeling 147,148. Ddit4 is upregulated in response to 
ischemia/hypoxia-induced damage 150. In addition, many genes that are broadly 
described as ‘cardio-protective’ were downregulated by MEF2A suppression including, 
notably, Notch 1; Thbs1 (thrombospondin 1) and NOS3 (nitric oxide synthase 3). It was 
previously shown that Notch 1 signaling reduces cardiomyocyte apoptosis in ischemic 
post- conditioning 160,161. Thbs1 contributes to healing myocardial infarcts and also 
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protects against cardiac remodeling by regulating TGFβ signaling and promoting matrix 
preservation 162,163. Exogenous NOS3 expression in   myocardium  protects  the   heart 
from arrhythmia 164.  
Collectively, in general terms, it seems that loss of MEF2 function results in hyper-
activation of genes involved in apoptotic induction and cell death while concomitantly 
leading to a reduction in the levels of genes involved in myocyte survival. The 
compound effects of these global gene expression changes for cardiac myocyte survival 
are clearly emphatic and of important clinical concern. Of note here is that in three 
independent large scale studies, the efficacy of β-adrenergic blockade in heart failure 
patients was reproducible and resulted in an approximate reduction by a third in the risk 
of death 165. A statistic that is unparalleled by any other drug used to treat heart failure 
165. On the basis of our studies, our tenet is that there are no doubt multiple 
mechanisms contributing to this favorable outcome, one of which might be enhanced 
cardiac myocyte survival mediated by MEF2- dependent gene expression. Our 
observations, in combination with those of other groups, suggest the possibility of a 
general role for MEF2 in cell survival. In particular, MEF2 has been implicated in 
neuronal survival 17 and, in the current study, protection from cardiomyocyte cell death. 
Whether MEF2 has a general pro-survival role in other tissues is currently unknown. So 
far, MEF2 has been implicated in the control of gene expression and differentiation in 
neurons, cardiac, skeletal and smooth muscle, T and B cells, adipocytes and 
osteoblasts 13,18,96,166–169. It will therefore be of interest to determine in these other 
MEF2-dependent cell types whether cell survival is anancillary function of its activity 
apart from its better-characterized role in cellular differentiation. Gene targeting studies 
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indicate that MEF2A has a role in cardiac metabolism, including regulation of fatty acid 
oxidation in the heart and maintenance of mitochondrial function 30. Activation of 
caspase 9 and the role of mitochondria in catecholamine-induced apoptosis in 
cardiomyocytes has also been documented 115. In view of these reports, it is likely that 
MEF2 protects against the mitochondrial-induced cell death pathway. 
In view of the seemingly central role had by MEF2 in the control of gene expression in 
the heart, signal pathway regulated control of MEF2 activity could offer a broad   target   
for therapeutic intervention. Research to date has indicated that MEF2 is a conduit for 
several signaling pathways that are regulated by a variety of cellular signaling 
pathways. To date MEF2 activity has been shown to be directly modulated by p38 MAP 
kinase 152,170,  ERK5/BMK1  36 , PKA  134 and CDK4 171 kinases, which are themselves, 
controlled by a myriad of signaling pathways. Therefore, there are many nodes that 
constitute potential rheostats in regulating MEF2 activity in the heart by means other 
than β-adrenergic blockade. One distinct and immediately applicable possibility is 
through the use of HDAC inhibitors. Several studies have indicated that class II HDACs 
are the most potent physiological repressors of MEF2 activity 172,173. Since there are 
numerous well-characterized inhibitors of HDACs, some of which are in clinical trials, 
their utility to de-repress MEF2 activity in some cases may   be worth consideration. 
Thus, signaling pathway diversity may provide considerable flexibility in targeting MEF2 
under conditions in which it’s activity is necessary or advantageous, such as during 
acute impending cardiomyocyte cell death, as well as under conditions when its activity 
needs to be restricted, such as under chronic conditions leading to cardiomyocyte 
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hypertrophy in which MEF2 contributes to cell enlargement by activation of fetal 
structural genes. 
Summary 
Our knowledge of the mechanisms controlling cardiac myocyte cell death is still quite 
incomplete. On the basis of our observations, we propose that the transcriptional 
regulator MEF2 fulfils a critical pro-survival function in cardiac myocytes having 
important implications for our understanding and therapeutic targeting of myocyte cell 
death and left ventricular pathology. 
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Figure 14. Summary of MEF2 regulation by β-adrenergic signaling in 
cardiomyocyte survival. On the left side, acute activation of β-adrenergic receptors 
invokes cAMP-mediated PKA activation in cardiomyocytes, resulting in suppression of 
MEF2 transcriptional activity by direct phosphorylation. Expression of pro-survival genes 
such as KLF6 is prevented resulting in enhanced cardiomyocyte death. On the right 
side, β-blockers, such as Atenolol, competitively inhibit the activation of the β-
adrenergic receptors by agonists resulting in enhanced MEF2 activity, thereby 
promoting cardiomyocyte survival. 
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Material and Methods 
Cell culture 
Primary neonatal rat cardiomyocytes were prepared from 1- to 3-day old Sprague 
Dawley rats using the Neonatal Cardiomyocyte Isolation System (Worthington 
Biochemical Corp, Lakewood, NJ, USA). Briefly, whole hearts were dissociated with 
trypsin (Promega, Madison, WI, USA) and collagenase (Worthington Biochemical Corp). 
The cells were re-suspended in Dulbecco's modified Eagle's medium F12 (Gibco, 
Burlington, ON, Canada) supplemented with 10% fetal bovine serum, 1% penicillin/ 
streptomycin and 50 mg/l gentamycin sulfate (Invitrogen, Burlington, ON, Canada). The 
isolated cells were plated for 60 min in 37 °C humidified incubator with a 5% CO2 in air, 
allowing differential attachment of non-myocardial cells. The cardiomyocytes were 
counted and transferred to gelatin-coated plates. The day after, medium was removed 
and replaced by fresh medium. For pharmacological treatments, cells were serum 
starved for the indicated time and replenished with fresh medium every 24 h. 
Atenolol administration in vivo 
MEF2-LacZ transgenic sensor mice, reported previously,134,151–153 were used in this 
study. Two groups of male mice (n = 5/each group) at 6–7 weeks were used. β-Blockers 
were administered through drinking water (Atenolol; 50 mg/kg per day) or solvent (5 ml 
water) for 2 days. Mice were sacrificed by cervical dislocation. The apex of each heart 
was fixed with 2% paraformaldehyde in PBS for 30 min. After being washed three times 
with PBS, the samples were incubated at 37 °C with X-Gal staining solution (5mM 
ferrocyanide, 5mM ferricyanide, 2mM MgCl2, and 1 mg/ml X-Gal) to visualize β-Gal 
positive cells. Samples were examined using bright field microscopy. 
	   67	  
Reagents and antibodies 
Rabbit polyclonal MEF2A antibody was produced with the assistance of the York 
University (Toronto, ON, Canada) Animal Care Facility. MEF2D (BD Biosciences, 
Mississauga, ON, Canada, 610775), KLF6 (Santa Cruz, Dallas, TX, USA, R-173 and E-
10), Actin (Santa Cruz, sc-1616), IRDye 680RD goat anti rabbit (LI-COR, Bioscience, 
Lincoln, NE, USA) and IRDye 680RD goat anti-mouse (LI-COR, Bioscience) were used 
for Immuno-blotting experiments. FITC- and TRITC-conjugated α-rabbit and α-mouse 
secondary antibodies and 4,6-diamidino-2-phenylindole (DAPI; D9542), H2O2 (H0904) 
and H89- dihydrochloride hydrate (B1427) were purchased from Sigma Aldrich 
(Toronto, ON, Canada). Atenolol (Sigma Aldrich, A7655), Isoproterenol hydrochloride 
(Sigma Aldrich, 1351005) and ICI 118551 hydrochloride (Abcam, Toronto, ON, Canada, 
ab1200808) were purchased for use in cell culture. 
Plasmids 
The firefly luciferase reporter gene plasmid pGL3–4xMEF2-Luc was made from pGL3-
MEF2-Luc with three additional copies of the MEF2 site inserted.10 ANF and ANF 
ΔMEF2 reporter constructs (consist of the firefly luciferace cDNA driven by 700 bp of rat 
ANF promoter sequence), provided by Dr. M. Nemer (Faculty of Medicine, University of 
Ottawa). The expression plasmid of pCMV-β-galactosidase has been described 
previously 134. The expression plasmid for pCIneo-KLF6 was a provided by Dr. S. 
Friedman (Mount Sinai School of Medicine, New York, NY, USA). KLF6 reporter 
constructs pROM6 and pROM3-Luc were provided by Dr. N.P. Koritschoner (Faculty of 
Bioquimica y Ciencias Biologicas, Universidad Nacional del Litoral, Santa Fe, 
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Argentina). pROM6 reporter construct containing the mutated MEF2-binding site 
(pROM6 ΔMEF2) has been described previously 17. 
siRNA-mediated gene silencing 
Gene silencing of target genes was done using siRNA technology; siRNAs were 
purchased from Sigma Aldrich. siMEF2A#1 (SASI_Mm01_00120787), siMEF2A#2 
(SASI_Mm01_00120788) and siMEF2D#1 (SASI_Rn01_00057714), siMEF2D#2 
(SASI_Rn01_00057709), and siMEF2D#3 (SASI_Rn01_00057717) were used at 100 
nM concentrations. We also used siKLF6#1 (SASI_Rn01_ 00082277), KLF6#2 
(SASI_Rn01_00082278) and KLF6#2 (SASI_Rn01_ 00082280) at 100 nM 
concentrations. 
Transfections 
Primary cardiomycoytes were transfected using Lipofectamine 2000 (Invitrogen) in a 
1:2.5 mixture ratio of DNA to lipofectamine in Opti-MEM	   (Invitrogen) according to the 
manufacturer’s instructions. Cells were re-feed and allow for recovery for 24 h before 
harvesting, or pharmacological treatments. For siRNA experiments, Lipofectamine 
RNAiMAX (Invitrogen) was used according to the manufacturer’s instructions. Cells 
were harvested 48–72 h after transfection for western immunoblotting analysis to 
determine the efficacy of protein knockdown or flow cytometry analysis. 
Protein extraction 
Protein samples were kept on ice during the entire procedure. Cells were washed twice 
with cold 1x Phosphate buffered saline (PBS). After aspirating the last PBS wash, 1.0 
ml of cold 1x PBS was added to cells. Cells were then gently scraped with a rubber 
policeman and transferred to a new tube and then centrifuged for 5 min at 4 °C. After 
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removing the PBS, the pellet was diluted with five times its volume in NP-40 lysis buffer 
(supplemented with 1mM sodium orthovanadate, 1mM PMSF and protease inhibitor 
cocktail (Sigma, P-8340). Cells were vortexed briefly every 10 min for a total of 40–45 
min, and centrifuged at high speed and supernatant was transferred to a fresh tube. 
Protein concentrations were determined by Bradford assay (Bio-Rad) with bovine serum 
albumin as a standard. 
Immunoblots 
Cells were harvested using an NP-40 lysis buffer (0.5% NP-40, 50mM Tris, 150mM 
NaCl, 10mM sodium pyrophosphate, 2mM ethylene diamine  tetra acetic acid and 
100mM NaF), containing protease inhibitor cocktail (Sigma Aldrich), 1mM phenyl methyl 
sulfonyl fluoride (Sigma Aldrich) and 1mM sodium orthovanadate (Bioshop, Burlington, 
ON, Canada). Total protein extracts (20–25 µg) were diluted in sample buffer (SDS 
polyacrylamide) containing β- mercaptoethanol, boiled for 5 min and electrophoretically 
resolved by 10% SDS-polyacrylamide gels, then transferred onto Immobilon-FL 
polyvinylidene difluoride membrane (Millipore, Fisher Scientific (distributor) Ottawa, ON, 
Canada). Non-specific binding sites were blocked with Odyssey Blocking Buffer (LI-
COR). Membranes were incubated with primary antibodies overnight at 4 °C in Odyssey 
Blocking Buffer. Primary antibodies included MEF2A (1:250), MEF2D (1:500), KLF6 
(1:500) and actin (1:1000). The blots were then incubated with the appropriate 
secondary antibodies IRDye 680RD goat anti-rabbit (1:5000) and IRDye 680RD goat 
anti-mouse (1:5000) for 2 h at room temperature and were imaged using LI-COR 
Odyssey System. 
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Luciferase reporter gene analysis 
Transcriptional assays were done using luciferase reporter plasmids. The cells were 
harvested for these assays using lysis buffer (20mM Tris, (pH 7.4) and 0.1% Triton X-
100). Lysate was briefly vortexed and centrifuged at maximum speed for 15 min at 4 °C. 
Enzymatic activity was measured in each sample on a luminometer using luciferase 
assay substrate (E2820, Promega) and values obtained were normalized to β-
galactosidase activity and expressed as fold activation by arbitrarily setting the control 
condition to 1. All measurements were made in triplicate for at least three independent 
experiments. 
Statistical analysis 
Data shown are mean ± S.D. All data were verified in three independent experiments 
using the same batch of cardiomyocyte isolation. Independent two sample t-tests of all 
quantitative data were conducted, whereas a one-way analysis of variance followed by 
a Tukey HSD post hoc test was performed on experiments with greater than two 
conditions. P-values are indicated with respect to controls where appropriate and P 
<0.05 was considered statistically significant. 
Flow cytometry 
Flow Cytometry analysis was performed as previously described 17 using the annexin V-
FITC apoptosis detection kit (APOAF, Sigma) following the manufacturer’s instructions. 
Primary cardiomyocytes were washed, briefly trypsinized, and then washed twice with 
cold PBS. Cells were pelleted by centrifugation and re-suspended in binding buffer 
followed by incubation with staining solution (annexin V-FITC and PI) for 15 min in the 
dark at 4 °C. The cells were re-suspended in binding buffer. Samples were analyzed 
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immediately by flow cytometry fluorescence, respectively. Ten thousand cells from each 
sample were scanned and analyzed by FACS Calibur flow β-Blockers enhance MEF2 
mediated cardiomyocyte survival	   cytometry (BD, Mississauga, ON, Canada) using the 
standard configuration and parameters. Data acquisition and analysis was performed 
using the Cell-Quest software (BD). Necrosis and apoptosis were determined by PI 
(FL2) and annexin V-FITC (FL1) fluorescence, respectively. 
Immunofluorescence 
Primary cardiomyocytes were fixed in 4% paraformaldehyde and permeabilized with 
0.3% Triton X-100 in PBS for 5 min. Cells were blocked with 10% goat serum in PBS for 
30 min at 37 °C and incubated overnight at 4 °C with primary antibodies MEF2D 
(1:100), MEF2A (1:100) and KLF6 (1:100) diluted in 1.5% goat serum. Cells were 
washed three times with PBS for 10 min and incubated with the appropriate TRITC- and 
FITC-conjugated secondary antibodies (1:500) in 1.5% goat serum for 2 hrs at room 
temperatur. DAPI staining (Sigma Aldrich) was carried out during the last 15 min. Cells 
were washed three times with PBS and images were captured using a Zeiss LSM 
confocal microscope (Carl Zeiss, ON, Canada). 
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CHAPTER 4 
 
HEART FAILURE AND MEF2 TRANSCRIPTOME DYNAMICS IN RESPONSE TO  
β-BLOCKERS χ	  
 
 
 
Summary 
Aims: Morbidity and mortality associated with cardiovascular disease (CVD) is a 
worldwide public health problem. β-blockers are a front-line treatment for heart failure 
(HF) yet the molecular characterization of their effects are incomplete. Transcription 
factor Myocyte Enhancer Factor 2 (MEF2) is an important mediator of cardiac 
remodelling and HF and is also a target of β- adrenergic signaling. The purpose of this 
study was to determine the global gene transcription networks that arise during HF with 
and without β-blocker treatment.  
Methods: Experimental HF by transverse aortic constriction (TAC) in a MEF2 “sensor” 
mouse model (6 weeks), was followed by four weeks of β-blockade (Atenolol-AT) or 
solvent (Sol) treatment. Transcriptome analysis by RNA-seq from corresponding left 
ventricular RNA samples and MEF2A depleted cardiomyocytes was performed. 
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Results: AT treatment resulted in an overall improvement in cardiac function of TAC 
mice and a decrease in cardiomyocyte size and fibrosis which was associated with 
repression of MEF2 activity. RNA-seq identified 65 differentially expressed genes 
(DEGs) due to TAC treatment with enriched GO clusters including cell proliferation, the 
immune system, cell migration and apoptosis. These genes were mapped against 
differentially expressed genes in cardiomyocytes in which MEF2A expression was 
suppressed. Non-coding RNA including lncRNAs were also assessed. Of the 65 TAC 
mediated DEGs, AT reversed the expression of a subset of 28 mRNAs and also 2 
lncRNAs. Rarres2 was identified as a novel MEF2 target gene that is upregulated with 
TAC in vivo and isoproterenol in vitro which has implications in cardiomyocyte apoptosis 
and hypertrophy. 
Conclusions: Chronic β1-blockade inhibits myocardial MEF2 activity while also 
contributing to dynamic changes in heart failure associated transcriptome dynamics. 
These studies identify a cohort of genes with vast potential for disease diagnosis and 
therapeutic intervention in heart failure. 
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Introduction 
Morbidity and mortality associated with cardiovascular disease (CVD) is a predominant 
global health problem occupying a prevalent position as the leading cause of death 
worldwide. Due to its universality, the multi-faceted progression of heart disease is 
therefore one of profound clinical importance. Progressive heart failure (HF), as one 
aspect of CVD, has a staggering prevalence of approximately thirty eight million 
diagnosed patients globally, a number which is growing due to the ageing population 
and the pervasiveness of HF in that age cohort 127,174. Moreover, a HF diagnosis in 
many cases is an ailment with a poorer prognosis than most cancers 127,174. 
Understanding and averting the progression of HF is therefore fundamental in the battle 
against CVD.  
A significant body of cellular and molecular research has elucidated the many structural 
and signaling changes associated with HF, while current advances in transcriptional 
analysis have begun to unravel the underlying dysregulation of the cardiac 
transcriptome in the pathogenesis of CVD and heart failure. At the molecular level, 
transcription is orchestrated by a complex set of interwoven cellular signaling pathways 
that converge in the nucleus to activate various transcription factors that are involved in 
driving the expression of the ultimately pathological gene expression program 4,48,175. 
Transcriptional circuits in post-natal vertebrate heart play a role in maladaptive cardiac 
hypertrophy and remodeling which are cardinal features of HF progression 4,48,175. 
Congenital disorders of structural and contractile proteins of the myocardium also lead 
to hypertrophy and eventual heart failure 48. Pathological remodeling of the heart is 
accompanied by increased apoptosis, fibrosis, alterations in cardiac gene expression, 
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assembly of new sarcomeres and activation of a ‘fetal’ set of cardiac genes 48. 
Accordingly, we hypothesized that pathological events underlying HF are accomplished 
by transcriptional dysregulation of a battery of genes involved in multiple biological 
processes.  
The regulation of the transcriptome in the heart is a primary determinant of its gene 
expression signature, phenotype and function 176–180. Extensive work concerning the 
control of cardiac specific gene expression 4,135–137,181,182 and also loss of function 
analysis in gene targeted mice 15,30,183 has positioned Myocyte Enhancer Factor 2 
transcriptional regulatory proteins (MEF2) at a nexus of control for cardiac and skeletal 
muscle gene expression. The MEF2 family of transcription factors (encoded by four 
genes labeled as MEF2A to D) have proved crucial in regulating cardiac 12, skeletal 
13,135 and smooth muscle differentiation 96, neuronal survival and plasticity 16,17 and T 
cell activation 18. The requirement for MEF2 is evolutionarily conserved for cardiac and 
skeletal muscle development from flies to humans 135. The N-terminus of MEF2 proteins 
(A-D) is conserved among all family members and consists of a 58-amino acid MADS 
domain and an immediately adjacent 28-amino acid MEF2 domain. These two domains 
collectively mediate dimerization, co-factor interactions and DNA binding to the 
consensus DNA sequence (C/T)TA(A/T)4TA(G/A) found in the regulatory region of most 
cardiac-specific genes 139. Interestingly, transgenic mice that express a constitutively 
active CaMKIV gene exhibit cardiac hypertrophy and, when cross-bred with a MEF2 
“sensor” mouse model, show markedly enhanced MEF2 activity 10. There is further 
molecular and correlative data that MEF2 activity is enhanced during cardiac 
hypertrophy, but to date how this modulates the progression of disease in vivo is 
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unclear. MEF2 is highly responsive to several signal transduction cascades, and post-
translational regulation by covalent modification by PKC 184, p38 MAPK 152,170,184, ERK5 
36,185 and PKA have been documented by ourselves 134 and others 186,187. In view of the 
central role of MEF2 in the control of cardiac transcription we view MEF2 activity as a 
barometer of extensive transcriptional changes in the heart. Moreover, because of the 
role of β-adrenergic signalling in heart disease and its associated control of cardiac 
MEF2 activity, we postulated that this may be of potential relevance in the pathology of 
the heart.  
Clinically, β-adrenergic receptor (βAR) antagonists, or β-blockers, reduce heart rate 
(chronotropy) and the force (inotropy) of myocardial contraction. Chronic heart failure in 
humans has been associated with impaired cardiac function, structural alteration, 
neurohormonal activation and use of β-blockers in humans with heart failure results in 
decreased mortality 114,130. Despite the well characterized effects of β-adrenergic 
blockers in modulating cardiac inotropic and chronotropic parameters and improving 
overall cardiac function, there is a surprising lack of information concerning how acute 
and, particularly, chronic β-blocker treatment affects cardiac gene expression. 
To date, the impact of pharmacologic treatment by β-blockers, a first line HF treatment, 
on global transcription changes during HF has not been reported. Therefore, we have 
begun to assess the relationship between global gene transcription and heart failure, 
particularly in response to β1-adrenergic blockade. Here, we report dynamic changes in 
cardiac gene transcription and MEF2 activity in response to HF, and document a subset 
of these genes that respond to pharmacologic manipulation by β1-adrenergic blockade.     
 
	   77	  
Methods 
Induction of pressure overload by transaortic constriction (TAC) in mice. Six to 
eight week old MEF2-LacZ transgenic male sensor mice, reported previously 151, were 
used in this study. Under general anesthesia (i.p. xylazine: 0.03 mg/g; ketamine: 0.15 
mg/g), hair from the chest was removed and the surgical area disinfected with betadine. 
A skin incision was made along the midline from the neck to the rib cage and the chest 
cavity was opened. The rib cage and thymus were retracted to expose the transverse 
aorta. A 27g needle was used to calibrate a microclip applicator. A titanium microligation 
clip was applied between the origins of the innominate and left common carotid arteries, 
constricting the transverse aorta to the gauge of the needle. The rib cage, muscles, and 
skin were closed with a 6-0 USP non-absorbable silk suture. The animals were then 
administered s.c. 0.03 µg/mg Buprenorphine and allowed to recover on a heating pad 
until fully awake. Sham surgeries were performed as above except the microligation 
was not applied to the transverse aorta. All mice were monitored after the procedure for 
normal behaviour in accordance with Canadian Council on Animal Care regulations. 
Atenolol administration in vivo and β galactosidase staining. β-blockers were 
administered through drinking water (Atenolol; 50mg/kg/day) or solvent (5 ml water) for 
10 weeks. Mice were sacrificed by cervical dislocation and the apex of each heart was 
fixed with 2% paraformaldehyde in PBS for 30 minutes. The samples were washed 
three times with PBS, and incubated at 37 °C with X-Gal (5-bromo-4-chloro-3-indolyl-β-
d-galactopyranoside) staining solution (5 mM ferrocyanide, 5 mM ferricyanide, 2 mM 
MgCl2, and 1 mg/ml X-Gal) to visualize β-Gal positive cells. Then all the samples were 
examined using bright field microscopy.  
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Analysis of cardiac function using high-frequency ultrasound imaging 
technology. All mice were subjected to transthoracic echocardiographic analysis to 
measure heart function 6 and 10 weeks following aortic banding or sham surgery. 
Cardiac function and heart morphology were evaluated using echocardiography (Vevo 
2100, VisualSonics). The animals were sedated using 3% isoflurane and maintained 
with 1~2% isoflurane. The parasternal long axis view (B-mode, M-mode) was obtained 
and measurements of cardiac structure and function were determined as described 
previously 188. The individuals performing echocardiographic analysis of heart function 
were blinded to surgical group and genotype. 
Cardiac tissue collection, H&E, Masson’s Trichrome, and wheat germ agglutinin 
staining (WGA) staining. Following echocardiography, mice were weighed and 
euthanized using cervical dislocation. Hearts were excised and quickly perfused with 
30mM KCl to induce diastolic arrest. Hearts were then weighed and divided for further 
analysis. Mid-ventricular cross-sections of freshly dissected heart tissue were fixed in 
10% formalin solution for 1 hour then stored in 70% ethanol at 4oC until further 
processing. Fixed heart tissues were dehydrated to xylene and embedded in pure 
paraffin wax blocks. Paraffin-embedded sections were deparaffinized and rehydrated 
first with descending concentrations of ethanol and then brought into double distilled 
water. The sections were then subjected to H&E or Masson’s Trichrome staining per 
manufacturer’s instructions, or incubated with wheat germ agglutinin (WGA; Alexa Fluor 
488 conjugated) for 2 hours in the dark, briefly washed with PBS and then mounted on 
microscopy slides with ProLong Gold. Fluorescent images were captured with an 
Olympus confocal microscope and analyzed with NIH ImageJ software (v.147). 
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Cardiomyocyte cross-sectional area data from at least 100 cells were determined per 
group from representative triplicate experiments. 
Primary cardiomyocyte isolation. Primary neonatal rat cardiomyocytes were prepared 
from 1- to 3-day old rats (Sprague Dawley) using the Neonatal Cardiomyocyte Isolation 
System (Worthington Biochemical Corp). Neonatal rat pups were sacrificed by 
decapitation. In brief, whole hearts were dissociated and digested with trypsin 
(Promega) and collagenase (Worthington Biochemical Corp). Cardiomyocytes were re-
suspended in culture medium with (DMEM/F12 (Gibco) with 10% fetal bovine serum 
(FBS), 1% Penicillin/Streptomycin and 50 mg/L gentamycin sulphate). The isolated cells 
were plated on 10 cm dishes for 60 minutes in 37oC humidified incubator with a 5% 
CO2 in air to remove non-myocardial cells. The cardiomyocytes were then seeded into 
gelatin-coated 6-well plates. The day after, medium was removed and replaced by fresh 
medium. 
Cardiomyocyte transfection. Neonatal cardiomyocytes were transiently transfected 
with siRNA using Lipofectamine RNAiMAX (Invitrogen). For each well, according to the 
manufacture’s instruction, Lipofectamine RNAiMAX reagent was diluted into 150 µl in 
Opti-MEM medium, and in a separate tube, siRNA (100nM) was also diluted in 150 µl 
Opti-MEM medium, mixed and incubated for 5 minutes at room temperature. The 250 µl 
of siRNA/Lipofectamine mixture was added to cells and incubated at 37°C overnight. 
Following the incubation, media was replaced and harvested 48 hours later for 
experimental procedures. The siRNAs purchased from Sigma Aldrich were, siMEF2A#1 
(SASI_Mm01_00120787) or scrambled control (SIC001). The siRNA purchased from 
Thermo Fisher Scientific were, siRarres2 (ID: 252512, ID: 252511), siJunb (ID: 59715, 
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ID: 51454), siAlas2 (ID: 468000, ID: 46614), siKLF2 (ID: 218080, ID: 218079) and 
siIigp1 (ID: 76220, ID: 76128). Isoproterenol hydrochloride (Sigma Aldrich, 1351005) 
(10µM) was used to induce apoptosis in primary cardiomyocytes. Caspase 3 (Cell 
signaling, 9662) and cleaved caspase 3 antibodies (Cell signaling, 9661) were used for 
western blot analysis and to measure apoptosis a ratio of cleaved caspase3 to total 
caspase3 was used.   
HL1 Cell Culture and Transfection. The HL-1 cardiac cell line was cultured in 
Claycomb Medium (SigmaAldrich) supplemented with 100µM norepinephrine (Sigma 
Aldrich), 10% FBS and 4 mM L-glutamine (Invitrogen). Cells were maintained in a 
humidified 37 °C incubator with 5% CO2. The HL-1 cell line was originally established 
from an AT-1 subcutaneous tumor excised from an adult female Jackson Laboratory 
inbred C57BLy6J mouse. Transient transfections were performed using lipofectamine 
2000. A 1:2.5 mixture ratio of DNA to lipofectamine in 250 µl Opti-Medium (Gibco) was 
prepared and incubated overnight. The day after medium was removed and replace by 
fresh medium. The HL-1 transfected cells incubated with wheat germ agglutinin (WGA; 
Alexa Fluor 637 conjugated) for 2 hours in the dark, briefly washed with PBS and then 
mounted on microscopy slides. Fluorescent images were captured with an Olympus 
confocal microscope and analyzed with NIH ImageJ software. 
RNA preparation for sequencing. Total RNA was isolated from the mouse left 
ventricle or primary rat cardiomyocytes using the Qiagen Universal RNA kit. Five µg of 
RNA was sent to the McGill University and Genome Quebec Innovation Centre 
(MUGQIC) for cDNA library preparation (Illumina Truseq mRNA kit). Paired reads were 
generated using Illumina HiSeq 2000 sequencer (100 bp paired-end reads). RNA-seq 
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data has been deposited in the NCBI’s Gene Expression Omnibus (GEO) accession 
number: GSE75213 
Differential expression analysis of transcripts from TAC+AT experiments. For 
mRNA mouse reads were aligned to mm10 as previously reported 143. Differentially 
expressed mRNA transcripts were filtered and identified with edgeR, using the following 
options: i) Transcripts are represented by 5 or more reads per million in at least 6 
among the 12 experiments. Transcripts are identified as differentially expressed in 5 
comparisons ii) Transcripts which are up-or downregulated by 50%, for a False-
Discovery-Rate (FDR) of 20% or less (in the output of edgeR’s glmLRT function) are 
selected. Clustering heatmaps were generated with Matlab’s Bioinformatics toolbox. 
Primary miRNA transcripts were identified using edgeR (adjusted p-value<0.2). To find 
lncRNA, short paired-end reads were mapped with RSEM/ Bowtie to the reference 
index (mm9) which was built for the 2073 mouse lncRNAs 189. All uniquely mappable 
short reads are included by using the bowtie-m 1 option in the rsem-calculate-
expression command. For identifying differentially expressed lncRNAs we used options 
that differed slightly from the analysis of protein-encoding transcripts:  i) Transcripts are 
represented by 5 or more reads per million in at least 5 among the 12 experiments. ii) 
Reads were multiplied by coefficients assuming equal library sizes for each of the 12 
experiments. iii) A two-factor generalized linear model design matrix was specified to 
estimate dispersion parameters. The Huber function with k=1.03 was used for robust 
statistics in the estimation of the tagwise dispersion parameters by the edgeR software 
190. LncRNAs are identified as differentially expressed in 5 different comparisons and by 
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using a False-Discovery-Rate (FDR) cut-off of 20% in the output of edgeR’s glmLRT 
function. 
Differential expression analysis of transcripts in primary rat cardiomyocytes. NGS 
short reads were mapped to the rat genome with the RSEM/ Bowtie software (Dewey 
Lab) and an index generated for 17349 mature transcripts in Rnor_6 coordinates. Raw 
counts were analysed with edgeR using similar identical parameters as in above: 
requiring that transcripts are represented by 5 or more reads in at least 3 out of 4 
experiments (2 siMEF2A replicates and 2 controls). In the MEF2A-depleted cardiac 
cells, 168 genes, excluding MEF2A, were significantly up- or downregulated, using an 
FDR of 25%. 
Quantitative real-time PCR. Total RNA was extracted using the RNeasy Plus Mini kit 
(Qiagen) according to manufacturer’s protocol. RNA was converted to cDNA using 
Superscript III (Invitrogen) according to the manufacturer’s instructions. Note that cDNA 
was combined with iTaq universal SYBR Green supermix (Bio-Rad) and 500 nM 
primers in a final volume of 20 µl.  Each sample was prepared in triplicate and analyzed 
using Rotor-GeneQ (Qiagen) according to the manufacturer’s protocol. All values were 
normalized to GAPDH (internal control) mRNA levels.  
Statistics. Data are reported as mean±SEM. Independent two sample t-tests of all 
quantitative data were conducted, whereas a one-way analysis of variance followed by 
a Tukey HSD post hoc test was performed on experiments with greater than two 
conditions. P-value of less than 0.05 was considered statistically significant. All data 
were done on technical triplicate and biological triplicate. The n=3 in the caption 
indicates the biological replicate.  
	   83	  
Study Approval. All mouse experiments were approved by the York University Animal 
Care Committee in accordance with Canadian Council of Animal Care regulations. 
 
Results 
β-adrenergic blockade attenuates the hypertrophic response to TAC, enhances 
cardiac function and reduces MEF2 activity 
Transverse aortic constriction (TAC) is a widely used in vivo model that mimics disease 
associated with cardiac hypertrophy and heart failure 191. The β1 selective β-adrenergic 
antagonist, Atenolol, is historically one of the most frequently prescribed of all 
medicines, and in experimental models such as TAC, Atenolol can prevent cardiac 
hypertrophy 192,193. Since MEF2 regulates a large battery of cardiac genes we were 
intrigued to further pursue these observations since it may have important clinical 
relevance for understanding the effects of chronic β-blocker treatment, which has been, 
and continues to be carried out in many millions of patients with cardiovascular disease. 
To study the effects of TAC and chronic treatment with Atenolol on MEF2 activity we 
initially utilized a MEF2-lacZ reporter transgenic mouse model. These mice harbour a 
synthetic transgene containing three MEF2 sites from the desmin gene distal to a 
heterologous promoter and exhibit MEF2 activity during development in the heart and 
somites 151.  Similar to previous studies with CAMKII activation 10, we observed that 
MEF2 activity is markedly enhanced by TAC during cardiac hypertrophy (Figure 15A) as 
we reported previously 194. Long term Atenolol (>10 weeks) treatment also reduced 
MEF2-activity in non-treated mice (Figure 15A). Mice at 6-8 weeks of age were 
randomized to receive either TAC surgery to induce left ventricular (LV) pressure 
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overload, or a sham operation. Assessment of heart function by transthoracic 
echocardiography six weeks after surgery demonstrating that TAC mice had developed 
physiological readouts characteristic of cardiac hypertrophy and the onset of heart 
failure: increased LV posterior wall thickness (PWDd) and LV mass, and decreased 
ejection fraction (EF) and fractional shortening (FS) (Figure S4). TAC or sham, mice 
were then treated with Solvent (Sol) or the β-blocker Atenolol (AT; 50mg/kg/day) for four 
additional weeks. After which time a series of comprehensive physiological, biochemical 
and genomic analyses were carried out. The four experimental conditions were 
therefore: Sham+Sol; Sham+AT; TAC+Sol; and TAC+AT (Figure 15A). 
After 4 weeks of treatment, TAC+Sol mice continued to exhibit signs of cardiac 
dysfunction and LV hypertrophy: reduced EF and FS, and increased PWDd, end 
systolic diameter (ESD), end systolic volume (ESV) and LV mass compared to 
Sham+Sol (Figure 15B). End diastolic diameter (EDD) and volume (EDV) were similar 
between the TAC+Sol and Sham+Sol groups. Atenolol treatment in the sham group 
(Sham+AT) induced no statistically significant change in heart function when compared 
to the control group (Sham+Sol). However, four weeks of Atenolol treatment in the TAC 
group (TAC+AT) resolved changes to LV geometry and reversed indices of LV 
hypertrophy induced by pressure overload as indicated by a reduction in ESD, PWDd 
and LV mass compared to TAC+Sol, and this was associated with an overall 
improvement in cardiac function, as evidenced by a significant increase in FS and EF in 
TAC+AT compared to TAC+Sol (Figure 15B). 
To further document the changes occurring in TAC mice treated with Atenolol, tissue 
sections were stained for wheat germ agglutinin (WGA) to visualize and quantitate 
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cellular hypertrophy (Figure 15C). TAC+Sol had larger cardiomyocytes than control 
(*P<0.05). Cardiomyocyte size in the TAC+AT group, however, was significantly smaller 
than in the TAC+Sol group indicating a reversal of the hypertrophic phenotype 
(#P<0.05). TAC and LV pressure overload is known to be associated with increased 
collagen deposition leading to fibrosis resulting in increased wall stiffness and ultimately 
decreased cardiac function 194,195. Masson’s trichrome staining showed increased 
fibrosis in the TAC+Sol group which was reduced in the TAC+AT group, as shown in 
representative images in Figure 15D. Together, these results demonstrate major 
positive effects of chronic Atenolol treatment on cardiac hypertrophy and heart failure 
progression. 
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Figure 15. Atenolol reverses heart failure symptoms in TAC mice. A) Experimental 
design overview. Left panel: MEF2-lacZ mice (6-8 weeks old) underwent transverse 
aortic constriction (TAC) or sham treatments, followed by Solvent or Atenolol 
(50mg/kg/day) treatment (n=9). Right panel: MEF2-LacZ activity in heart with chronic 10 
week β-blocker (Atenolol) treatment (50mg/kg/day). B) Functional analysis of TAC or 
Sham mouse hearts after four weeks of Atenolol or Solvent treatment. End systolic 
diameter (ESD), end diastolic diameter (EDD), ejection fraction (EF), fractional 
shortening (FS), end systolic volume (ESV), end diastolic volume (EDV), left ventricular 
mass (LV), and left ventricular posterior wall depth (PWDd) were assessed by 
ultrasound echocardiography. Data are presented as mean ±SEM. *P < 0.05 vs 
Sham+Sol.  # P < 0.05 vs TAC+Sol C) WGA stain depicting cardiac hypertrophy. 
Images are representative of an average of n≥10 images per heart, 4 animals per 
group. Scale bar: 25 µm. Graph below shows cardiomyocyte size (CM cell size), 
quantified based on an average of ≥10 cell measurements per mouse (n=4). Data are 
presented as mean ±SEM. *P < 0.05 vs Sham+Sol. # P < 0.05 vs TAC+Sol. D) 
Masson’s Trichrome stain depicting fibrosis. Images are representative of n=10 images 
per heart, 4 animals per group. Cardiomyocytes appear red, nuclei appear black and 
collagen appears blue. Scale bar: 100 µm. 
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Dynamic changes in gene expression provoked by TAC are reversed by β-
adrenergic blockade 
To further understand the underlying changes in gene expression during these 
conditions, the left ventricle was isolated from each condition (n=3 mice per condition) 
and RNA was prepared for subsequent RNA-Seq analysis to document transcriptome 
changes associated with the experimental treatments and potentially identify 
differentially expressed genes (DEGs). Across all conditions, 1571 DEGs were detected 
(Figure 16A). In particular, we documented 65 DEGs in TAC+Sol mice compared to 
Sham+Sol (Figure 16B). In parallel, some genes affected by Sham+Sol had a reversed 
pattern of expression in TAC+AT (Figure 16A, blue boxes). A complete list of all DEGs 
is in Dataset 1. Most importantly, one predominant feature of the data is that the pattern 
of differentially expressed genes in TAC+Sol was in general reversed in TAC+AT 
(Figure 16A, yellow boxes).  
To identify the potentially most biologically relevant DEG’s we focused on genes that 
were differentially expressed in both TAC+Sol vs Sham+Sol and TAC+AT vs TAC+Sol 
comparisons (32 genes), which comprised of nearly half of all DEGs in the TAC+Sol 
condition (Figure 16C). Figure 16D depicts the dynamic regulation of a sub-set of the 32 
genes identified in Figure 16C. In general, genes that were upregulated in TAC+Sol 
relative to Sham+Sol were downregulated in TAC+AT vs TAC+Sham, and vice versa for 
downregulated genes, demonstrating that Atenolol reverses the effect of TAC on gene 
expression in the heart. Among these genes were Klf2, Junb, Ier2 (immediate early 
response 2), Alas2 (delta-aminolevulinic acid synthase 2, two ubiquitin related proteins 
Ube2l6 (E2 ubiquitin ligase) and Usp53 that are upregulated in TAC, while Atenolol 
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reduces their expression in response to TAC. The upregulation of a and b chains of 
hemoglobin seen in TAC+Sol were also reversed by Atenolol treatment, an important 
feature since elevated hemoglobin has been associated with cardiac death 196. On the 
other hand Ifrd1 (also known as PC4; Tis7) is a known co-factor of MEF2 in skeletal 
myoblasts that contributes to skeletal myogenesis 197 is downregulated with TAC, but 
atenolol treatment induces expression relative to TAC+Sol. Down-regulation of tissue 
inhibitors of metalloproteinases (Timps) and upregulation of matrix metalloproteinases is 
also associated with extracellular matrix remodelling during heart failure 198,199. In our 
data, Timp-4, was downregulated with TAC and upregulated with Atenolol treatment. 
Timp-4 downregulation has also been associated with left ventricular dilatation in heart 
failure in humans 200.  
lncRNAs are non-coding RNAs greater than 200 nucleotides long and have increasingly 
been connected to cardiac development 189. Using a compiled network of lncRNAs 189 
we characterized DE lncRNA in our samples. The percentages of reads, which mapped 
to lncRNAs varied in a narrow range from 2.8% to 3.4% (Figure S5). It is important to 
point out that our analysis isolated poly-A containing transcripts, so any lncRNA without 
this modification would not be detected. However, our analysis showed that there are 84 
differentially expressed lncRNA across all conditions (Figure S5). Matkovich et al. 189 
found that expression in lncRNAs was most dynamically regulated during heart 
development in the embryo, and less so in a TAC model of cardiac hypertrophy. 
Similarly, we found 6 lncRNAs to be significantly regulated in TAC+Sol conditions, and 
12 were DE in TAC+AT vs TAC+Sol (Figure S5). An emerging role for lncRNA in 
cardiac hypertrophy is apparent, however to study the function of individual lncRNA will 
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take time because of the highly variant mechanisms proposed for their function. To 
initially identify some potential biological associations we assessed the five most 
abundant lncRNA in each condition and identified a lncRNA name in the literature (if 
present) (Figure S5). In all conditions, n413706, n415312 and n413977 were most 
abundant. n415312 has recently been identified as lncRNA Myheart (Mhrt) and is 
associated with regulation of Mhy7 201. Mhrt has a reported cardio-protective role 
through inhibition of the Brg1 chromatin remodeling factor 201. n424047, lncRNA 
MSUR1, was abundant in Sham+Sol but downregulated in all other conditions. MSUR1 
was able to prevent SOD1-mediated cell death 202. It may therefore be possible that 
MSUR1 also has a role in heart failure.  
We used a functional annotation clustering tool 203,204 to group terms with related 
biological meaning into annotation clusters. Annotation terms were manually selected 
from the list of representative terms generated within each cluster. The ten clusters with 
the highest enrichment score from each treatment are shown in Figure 17. TAC+Sol 
(Figure 17A) contained clusters enriched for cell proliferation, the immune system, cell 
migration and apoptosis. The most critical comparison was between TAC+Sol and 
TAC+AT (Figure 17B). Annotation clusters were related to the extracellular matrix, 
collagen and heparin binding, and also muscle protein.  
To draw out a more gene specific comparison, two representative GO clusters from 
Figure 17B are illustrated in Figure 17C corresponding to the ‘muscle protein’ (left) and 
‘heparin binding’ (right) identifiers. Terms within each annotation are on the X axis, while 
each gene associated with these terms is on the Y axis. Genes that were upregulated 
are red and genes that were downregulated are green. Fourteen genes were associated 
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within the ‘muscle protein’ cluster. Some upregulated genes of note include Mybpc2, 
Myh7, Acta1 and Des. Interestingly two of the affected genes were E3 ubiquitin ligases 
Trim63 and Trim72. Trim63, (also called MuRF1) was downregulated and has been 
previously associated with muscle atrophy 205. Trim72 (or MG53) was upregulated and 
is associated with membrane stability has been reported to target the insulin receptor 
for degradation 206.  In general genes associated with the heparin-binding cluster were 
downregulated in TAC+AT compared to TAC+Sol. Consistent with the high 
glycosaminoglycan binding properties of the protein products of these genes, several 
genes within this cluster are related to the extracellular space. Ccn1 is a matricellular 
protein whose expression has been associated with heart failure 207. Mice deficient for 
Col15a1 (type XV collagen) also have heart defects 208,209. Adamts1 and 8, two matrix 
metalloproteinases, are also known to be anti-angiogenic 210. Precise expression of 
Adamts1 during embryogenesis is involved with trabeculation of the heart but its role in 
the adult heart is not yet clear 211. 
In general, these data demonstrate that during TAC+Sol treatment genes associated 
with apoptosis and remodeling of the extracellular matrix are upregulated and Atenolol 
treatment remarkably reverses many of these transcriptome changes. In addition, 
TAC+AT resulted in an upregulation of muscle protein genes that are collectively 
associated with improved muscle function. 
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 Figure 16 
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Figure 16: Changes in gene expression caused by aortic constriction is reversed 
by atenolol treatment. RNA-seq analysis was completed on the left ventricle of mice 
that had undergone TAC or Sham operation for 6 weeks followed by either solvent or 
Atenolol treatments (n=3 in each group). A) Heatmap depicting changes in gene 
expression of 1571 protein coding genes. Genes are ordered based on hierarchical 
clustering. Genes up- or down-regulated by TAC alone, relative to control (leftmost 
column; yellow box). Effects of β-blocker (2nd leftmost column; blue box). B) Total 
change in up and downregulated genes in each condition. C) A select group of genes 
(32) were differentially regulated in both the TAC+Sol vs Sham+Sol and TAC+AT vs 
TAC+Sol conditions. D) Heatmap depicting the Fold Change values of TAC+AT vs 
TAC+Sham and TAC+Sol vs Sham+Sol.  
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Figure 17. Biological implications based on functional annotation gene clustering.  
A) TAC+Sol vs Sham+Sol. B) TAC+AT vs TAC+Sol. Function annotation clusters 
identified by DAVID using default settings with medium stringency. Annotation terms 
were chosen from the list of representative terms generated within each cluster. If 
present, the first SP_PIR_KEYWORDS was used as the annotation. If 
SP_PIR_KEYWORDS was not present the first BP term to occur in the cluster was 
used. Beside each annotation is the number of representative terms associated within 
each cluster. C) Two representative clusters from TAC+AT vs TAC+Sham. 
Representative terms within each cluster are on the X axis. Genes within each GO term 
are on the Y axis. Left: ‘Muscle protein’ (7 genes up, 7 down, 14 total). Right ‘Heparin 
binding’ (3 up genes, 13 down, 16 total). Grey indicates association of a gene with a 
representative term. Genes shaded red or green were up- or down-regulated, 
respectively. 
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The role of Klf2, Junb, Rarres2 and Alas2 in cardiomyocyte hypertrophy and 
apoptosis. 
To verify the differential regulation of individual genes in response to TAC and Atenolol, 
as depicted in Figure 19C and 19D in the transcriptomics data, we performed individual 
qRT-PCR on RNA samples from the same treatment conditions on 24 of the identified 
genes (Figure 18A, Figure S6, S7). Next, we selected 5 genes upregulated in TAC+Sol 
relative to Sham+Sol and downregulated in TAC+AT vs TAC+Sham (Klf2, Junb, 
Rarres2, Iigp1 and Alas2) for further analysis in the context of cardiac hypertrophy and 
apoptosis. Since two prominent features of progressive heart failure are cardiomyocyte 
hypertrophy and apoptosis, we decided to further test the capacity of the identified 
genes to affect these parameters in our in vitro models using gain and loss of function 
analysis. For the gain of function (GOF) analysis we chose to exogenously express the 
genes of interest. For loss of function (LOF) we used siRNA mediated depletion of the 
target genes. We then assessed GOF or LOF in two models: a) apoptotic induction by 
high-level Isoproterenol (Iso) induction in primary cardiomyocytes; and b) induction of 
hypertrophy in the cardiac HL-1 cell line. The rationale for choosing the particular genes 
that we did was that they were dysregulated under TAC conditions and, importantly, 
their expression pattern was substantially reversed with Atenolol treatment indicating 
that they may be involved in pathological changes that can be potentially altered by 
drug therapy. First, RT-PCR analysis confirmed that Klf2, Junb, Rarres2, and Alas2 are 
upregulated in response to TAC, and Atenolol treatment reverses this effect (Figure 
18A) similar to what was observed with TAC and Atenolol treatment in vivo in the 
transcriptome data (Figure 16).  
	   97	  
Next, cardiac HL-1 cells were transfected with GFP and expression plasmids for a 
number of genes of interest individually or in combination and the cells were stained for 
Wheat Germ Agglutinin (WGA) to visualize and quantitate the cell surface area as an 
index of cellular hypertrophy (Figure 18B). Only GFP+ cells were quantified in this 
analysis. The bar graph indicates the mean size of HL-1 cells transfected with the 
indicated expression plasmids individually or in combination compared to the vector 
alone control. These preliminary data indicate that, of the genes tested, Alas2, Junb and 
Klf2 may have a role in promoting cardiomyocyte hypertrophy since their exogenous 
expression in cultured HL-1 cells led to a trend towards increased cell surface area 
although Klf2 was the only significantly different treatment (p<0.05). To assess the 
potential role of Junb, Klf2, Rarres2, Alas2 and Iigp1 genes in cardiac apoptosis using 
LOF, we silenced their expression using siRNA technology and treated cardiomyocytes 
with isoproterenol (10µM) for 48 hours to induce increased levels of cardiac apoptosis 
as we have previously published 212. Protein expression of caspase 3 and cleaved 
caspase 3 (active form of caspase 3) was then determined as an indicator of apoptotic 
induction. Of the genes tested, expression of the active form of caspase 3 was reduced 
in siRNA-mediated depletion of Junb, Rarres2 and Klf2 treated with Iso compared to the 
control but depletion of Alas2 or Iigp1 had no effect (Figure 18C and Figure S8).  
These results demonstrate a possible pro-apoptotic role of Junb, Rarres2 and Klf2 
genes in primary cardiomyocytes. In summary, these preliminary in vitro data on the 
possible function of the genes identified in the in vivo transcriptomics data reveal a 
putative involvement of Junb, Rarres2 and Klf2 in apoptotic induction and a potential 
hypertrophic influence of Alas2, Junb and Klf2 in hypertrophy. Further in vivo studies of 
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these genes are thus warranted to determine their role in cardiac pathology.      
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Figure 18 
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Figure 18. Role of KLF2, Junb, Rarres2 and Alas2 in cardiomyocyte hypertrophy 
and apoptosis. A) Modulation of KLF2, Junb, Rarres2 and Alas2 expression in 
response to TAC and Atenolol as depicted in Figure 2C, was confirmed using qRT-
PCR. cDNA was analyzed via qRT-PCR using SYBR Green master mix. Data were 
normalized to Gapdh and are presented as fold change using the delta delta Ct method 
(n=3, *P<0.05 **P<0.01 Sham+Sol vs TAC+Sol, ++P<0.01 Sham+Sol vs Sham+AT, 
##P<0.01 TAC+Sol vs TAC+AT). B) WGA staining depicts cardiac hypertrophy. Cardiac 
HL-1 cells were transfected with GFP and Alas2, Junb, or KLF2 expression plasmids 
individually or in a mixture and stained with Wheat Germ Agglutinin (WGA) in red. The 
bar graph indicates that cell size of GFP positive HL-1 cells, quantified based on 5 cell 
measurements per image. Data are presented, as mean ±SEM. Scale bar is 10µm. C) 
Primary cardiomyocytes were transfected with two independent siRNAs, Junb siRNA, 
Rarres2 siRNA, KLF2 siRNA, (top panel), or with scramble siRNA control and treated 
with isoproterenol  (10µM) for 48 hours.  Equal amounts of total protein were used for 
western blot analysis and the levels of the indicated proteins were assessed by a 
standard immunoblotting technique using specific primary antibodies for each as 
indicated. Bar graph represents the quantified data, Caspase 3 bar graph represents 
cleaved Caspase 3 normalized to total caspase 3 (bottom panel). 
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Transcriptome profiling in MEF2A depleted cardiomyocytes and its relation to β-
blockade associated transcriptome changes.   
To determine how TAC and Atenolol influence MEF2 activity, MEF2 sensor mouse 
hearts were stained for LacZ expression. These data indicate that MEF2 activity was 
strongly induced in TAC+Sol mice and, in parallel with the positive reversal of other TAC 
induced changes, Atenolol treatment substantially reduced MEF2 activity (Figure 19A). 
We then assessed potential regulation of these differentially expressed genes (429) 
from the TAC+AT vs TAC+Sol analysis using oPossum 3.0 to find transcription factor 
consensus sequences within ±5kb of the transcription factor start site (data not shown). 
MEF2A consensus sequences were identified at 159 (37%) of differentially expressed 
genes. Next, we assessed predicted MEF2 consensus sequences from 32 overlapping 
genes upregulated in Figure 16D. RNA expression (FPKM) of these genes in heart 
muscle (Female, age 40-50) was also analyzed in Human Protein Atlas program (Figure 
S9). MEF2A, as a positive control, with FPKM >20 is highly expressed (+++) in heart 
muscle. In comparison, RNA levels (FPKM), Rarres2, Junb and Slc41a3 (++) have high 
heart muscle expression and Aldh1a2, Ifrd1, Klf2, Leo1 have lower expression (+).  
Since MEF2 activity was potently regulated by TAC and AT we next took a more 
reductionist approach by using siRNA-mediated MEF2 gene silencing to determine 
whether genes affected in the in vivo experiments were also influenced by MEF2A 
suppression in primary isolated cardiomyocytes. We reasoned that this approach might 
provide insight into the number of direct cardiomyocyte DEGs that were altered by β-
adrenergic blockade that were a consequence of altered MEF2 function. siRNAs 
targeting MEF2A were transfected into primary cardiomyocytes and prepared for RNA-
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sequencing in duplicate. In total there were 168 DEGs, where 107 of which were 
upregulated and 68 were downregulated (Figure 19B). Figure 5C demonstrates the 
log2FoldChange of the differentially expressed genes in a volcano plot. The overall 
features of this plot reveal an extensive re-patterning of cardiomyocyte gene expression 
when MEF2A is depleted. Of note, Mef2a downregulation was coincident with 
downregulation of cytokines Cxcl6 (rat homologue to mouse Cxcl5) and Cxcl10 while 
Bnip3, which is involved in apoptotic induction, was upregulated. We have previously 
identified a protective role of MEF2A in cardiomyocyte survival 212. It will be interesting 
to determine if upregulation of Bnip3 is involved in apoptotic induction when MEF2A is 
silenced- a condition that does occur with acute β-adrenergic stimulation 115.  
Next we assessed the biological significance of the function of these genes using Gene 
Ontology analysis. Figure 19D shows the ten most enriched Biological Processes 
associated with MEF2A depletion. Interestingly, a number of these terms are related to 
cell death and the inflammatory response. 
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Figure 19 
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Figure 19. Involvement of MEF2 in cardiac hypertrophy and death.  A) Hearts from 
TAC+Sol and TAC+AT (n=3) were stained for LacZ expression. B) The number of 
genes up or downregulated in response to MEF2A knockdown in primary 
cardiomyocytes. Table of genes regulated by MEF2, (upregulated are in red, 
downregulated are in blue). C) Volcano plot depicting up and downregulated genes 
identified in RNA-seq in response to MEF2A knockdown in primary cardiomyocytes. 
Black if p-value>0.05, red if p-value<0.05, green if log2FoldChange>1 or <-1 and p-
value<0.05. Labels are present only on logFC>±1.5. E) GO Biological Processes 
associated with up or downregulated genes. The number of genes is in parentheses 
beside each term. 
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Rarres2 is a novel MEF2 target gene regulated by β-adrenergic signaling.  
In comparing our transcriptome profiles from Figure 16D to those affected by MEF2A 
knockdown in vitro we were particularly interested in the identification of the Rarres2 
mRNA. This gene encodes a protein for the adipokine Chemerin that is mainly produced 
in liver and adipose tissue, and is also highly expressed in heart muscle based on the 
Human Protein Atlas analysis in Supplementary Figure S6. Previous studies have 
shown that treatment of cardiomyocytes with Chemerin affects caspase 9 activity and 
induction of apoptosis 213. The expression (FPKM) of Mef2a and Rarres2 from the RNA-
seq data is shown in Figure 20A indicating efficacy of the gene silencing and an 
upregulation of Rarres2. From our in silico analysis using oPossum, we found a putative 
MEF2 consensus sequence approximately 1 kb upstream from the transcription start 
site. Using primers flanking this region we performed ChIP-qPCR and validated MEF2A 
recruitment in primary cardiomyocytes to this locus (Figure 20B). We also determined 
that loss of MEF2A and MEF2D had a similar effect on Rarres2 induction (Figure 20C). 
Figure 20C depicts cardiomyocyte treatment with the p38MAPK inhibitor (SB 203580) 
for 24 hours which led to upregulation of Rarres2 expression and this effect is reduced 
when cardiomyocytes were transfected with a MEF2A mutation (MEF2A-T312, 319A) 
which is refractory to p38MAPK phosphorylation. We also observed that Rarres2 is 
upregulated in cardiomyocytes by β-adrenergic signalling activation (Isoproterenol 
treatment-Figure 20D), similar to what was observed with TAC treatment in vivo (Figure 
16, 18A). Taken together, these data indicate that Rarres2 is a p38 MAPK/MEF2 
regulated gene that is induced in heart failure. 
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 Figure 20 
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Figure 20. Rarres2 is regulated by MEF2. A) Expression of Mef2a and Rarres2 in 
RNA-seq analysis of MEF2A depleted cardiomyocytes (fragments per kilobase of exon 
per million fragments mapped). B) MEF2A recruited to the Rarres2 promoter in primary 
cardiomyocytes. Data are presented as fold enrichment (n=3, *P<0.05). Acta2 was used 
as a negative control. C) Rarres2 expression is negatively regulated by MEF2 in a p38 
MAPK dependant manner in primary cardiomyocytes. Cardiomyocytes were transfected 
with siRNA targeting MEF2A or MEF2D. Cells were also transfected with scramble 
siRNA control (left panel) and empty vector (pcDNA3) or MEF2A mutated form MEF2A 
(T312, 319A) (right panel) and treated with SB 203580 (5 µM) for 24 hours and 
analyzed for changes in Rarres2 mRNA. Control cells were treated with an inactive 
analogue, SB 202474. Data were normalized to Gapdh and are presented as fold 
change using the delta delta Ct method (n=3, *P<0.05, **P<0.01). D) Isoproterenol (Iso; 
10 µM) treatment for 24 hours, upregulates Rarres2 expression. Data were normalized 
to Gapdh and are presented as fold change as was done in 6C (n=3, **P<0.01). 
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Discussion 
Understanding the global gene networks associated with heart failure will provide critical 
insight into the underlying aetiology of heart disease while also providing an 
unprecedented array of molecular targets for therapeutic intervention. In the work 
presented here we have used next generation RNA sequencing based approaches 
coupled with bioinformatics to document transcriptome changes associated with 
experimental heart failure. Moreover, we have documented gene expression changes 
mediated by β−adrenergic antagonism that result from a partial reversal of a heart 
failure associated gene signature that is coupled with improved cardiac function.  
Underlying the transcriptome changes that we have observed are dynamic changes in 
the activity of a fundamental cardiac transcriptional regulator, MEF2.  The potent 
influence of β-adrenergic blockade in regulating MEF2 function in the heart has been 
highlighted recently 212. However, the influence of β-blockers on MEF2 function in the 
heart is complex and requires attention to context since MEF2 responsiveness to β-
blockade depends on the temporal nature of the treatment.  Firstly, short term β-
blockade leads to an acute upregulation of MEF2 activity 212. Mechanistically this is well 
understood since β-adrenergic signalling promotes PKA activity and HDAC nuclear 
retention 214. Both of these have strong repressive effects on MEF2 activity since PKA 
phosphorylates two residues in MEF2D (S121/190) that repress MEF2 function and 
HDAC retention in the nucleus enhances the formation of a MEF2/HDAC repressor 
complex 134. We have recently reported that acute β-blockade essentially reverses this 
effect and upregulates MEF2 activity promoting a pro-survival function of MEF2 in 
cardiac myocytes that has potentially important clinical implications, particularly after 
	   109	  
myocardial infarction 212. In support of this idea, we and others recently documented 
that experimental suppression of MEF2 expression in rodent cardiomyocytes using 
siRNA technology promotes apoptosis 212,215. Conversely, as we have shown here and 
somewhat unexpectedly, MEF2 activity under conditions of chronic (>4 weeks) β-
adrenergic blockade leads to a downregulation of MEF2 activity, particularly under 
conditions where the heart is stressed as exhibited under conditions of TAC in mice. In 
our experiments long term (>6 weeks) TAC in mice leads to cardiac hypertrophy, 
progression to heart failure, and pronounced activation of MEF2 activity. Treatment of 
mice at 6 weeks after TAC by four weeks of β-adrenergic blockade reduces the adverse 
impact on heart function and concomitantly suppresses chronic MEF2 activity while also 
invoking major transcriptome changes. In view of reports that MEF2 is a fundamental 
regulator of cardiac hypertrophy 31,182 and our results documenting the transcriptomic 
effects of MEF2 suppression in cardiomyocytes, we suspect that alterations in MEF2 
activity are a major determinant of the transcriptome changes observed in response to 
TAC and also the positive outcome associated with β-adrenergic blockade.     
 Of particular interest in our studies are the gene expression changes that are induced 
by experimental heart failure and subsequently reversed by β-blockade since, in our 
view, some of these genes most likely mediate the protective effects of β-blockers in the 
heart. Cardiac hypertrophy is initially an adaptive compensatory mechanism to maintain 
cardiac output, however, prolonged hypertrophic conditions such as those seen during 
hypertension ultimately contribute to the progression towards heart failure 216. Although 
β−blocker treatment in humans post-MI is undoubtedly effective in preventing or slowing 
the progression to heart failure, the molecular mechanisms involved are unclear. Here 
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we provide the first steps in characterizing the molecular genetic basis of beneficial 
β−adrenergic antagonists in the heart. In this cohort we have identified 32 genes that 
are differentially regulated by TAC whose expression pattern is reversed when TAC 
mice are treated with β-blockers. We explored the role of Junb, Alas2, Klf2, and Rarres2 
in cardiomyocyte hypertrophy and apoptosis as they were induced by TAC in vivo but 
their expression was repressed by Atenolol (Figure 18A). Two of these (Junb and KLF2) 
are transcription factors whereas Alas2 regulates heme synthesis and Rarres2 (which 
encodes Chemerin) is an adipokine. Interestingly, these four different genes potentiate 
different aspects of heart failure including oxidative stress, hypertrophy, cardiac 
remodelling, vascular remodelling and apoptosis. Alas2 was shown to be upregulated in 
failing human hearts, resulting in oxidative stress and cell death 217. In our experiments 
loss of Alas2 in primary cardiomyocytes did not reduce apoptosis as cleaved caspase 3 
was unaffected (Figure S8), indicating that Alas2 may promote cardiomyocyte death 
through alternate pathways.  Junb is directly responsible for the upregulation of Mmps 
which mediate cardiac remodelling in ischemia-reperfusion studies 218 therefore it is 
important that Atenolol can reverse its expression. Klf2 has been shown to be activated 
in endothelial cells by shear stress 219. In our TAC model, constriction of the aorta 
results in increased hemodynamic stress, and likewise results in Klf2 induction which is 
reversed by Atenolol. Lastly, Rarres2 was also upregulated in MEF2A knockdown 
cardiomyocytes in vitro, and has been previously associated with cardiac apoptosis and 
coronary artery disease 213. It would be of interest to study β-adrenergic and MEF2 
regulation of Rarres2 in more detail in human heart disease. Taken together, these data 
indicate a potential involvement of these genes in the failing mouse heart that may have 
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implications in human heart failure. Furthermore, the identification of genes associated 
with heart failure that are downregulated by Atenolol (such as Junb, Klf2, Alas2, and 
Rarres2) demonstrates the underlying molecular changes responsible for improved 
heart function, which may lead to new downstream targets for treating heart failure.  
Overall, we contend that the cohort of DEGs reported here represent vast potential for 
the diagnosis and treatment of heart disease. Interestingly, we have noted considerable 
identification of genes and GO processes associated with the immune system. These 
observations support recent developments reflecting the involvement of the immune 
system and inflammatory responses in the progression of heart disease 220–222. It will be 
of interest to further analyze these immune system related protein coding genes and 
non-coding RNAs to determine if they do indeed contribute to heart disease. Herein, we 
report broad categories of biological processes and also individual genes and non-
coding RNAs that are differentially regulated under conditions of experimental heart 
failure that can be reversed by pharmacological treatment with β-adrenergic 
antagonists. The next steps will be to determine whether these changes are mirrored in 
human heart disease and to develop a flexible array of therapeutics that can detect and 
potentially target these processes with the ultimate aim of reducing pathological 
changes in the myocardium, enhancing cardiac function, and improving patient 
morbidity and mortality associated with heart disease. 
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CHAPTER 5: Summary and Discussion 
          The focus of this dissertation was to investigate a potential clinically important link 
between the pharmacological blockade of β-adrenergic signaling in the heart and MEF2 
transcriptional regulators as global regulators of cardiac gene expression. The influence 
of β-blockers on MEF2 function in the heart is complex since MEF2 responsiveness to 
β-blockade depends on the temporal nature of the treatment. In the first manuscript, the 
short-term effect of β-blockade in regulating MEF2 function in the heart has been 
investigated. In the first set of experiments, it was observed that β-blockade 
antagonizes β-adrenergic mediated apoptosis while concomitantly enhancing MEF2 
transcriptional activity promoting a MEF2 pro-survival function in cardiomyocytes. In 
addition, β-adrenergic mediated apoptosis was abrogated in cardiomyocytes expressing 
a PKA-resistant form of MEF2D (S121/190A). Mechanistically this is well understood 
since β-adrenergic signaling enhances PKA activity and also nuclear retention of 
HADCII. Both of these mechanisms repress MEF2 activity since PKA phosphorylates 
two residues in MEF2D (S121/190) that repress MEF2 function and increased HDACII 
retention in the nucleus enhances the formation of a MEF2/HDAC repressor complex 
134. Furthermore, KLF6, a MEF2 target gene in the heart, functions as a downstream 
pro-survival factor in cardiomyocytes (Figure S1, News and Commentary, 223). Also in 
support of this idea, siRNA depletion of MEF2 expression promotes cardiomyocytes 
apoptosis and up-regulation of apoptotic genes as assessed by RNA-Seq analysis. 
Based on this evidence I propose that increased adrenergic drive and PKA signaling in 
pathological remodeling inhibits MEF2 pro-survival activity, which contributes to 
cardiomyocyte cell death post myocardial infarction (MI). Interestingly, β blockade 
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inhibits PKA activation and reduces infarct mediated cell death post MI and, based on 
our data, this may result from MEF2 pro-survival activity. This needs to be clarified in an 
in vivo model of MI. It would therefore also be interesting to investigate alternative ways 
of activating MEF2 transcriptional activity acutely through different mechanisms in the 
infarcted heart. Recently we also reported that adiponectin can contribute to MEF2 
activation in the heart by p38 MAPK activation, indicating another possible pathway to 
activate MEF2 that might allow pharmacological involvement of Adiponectin 194. In 
general, such an approach would allow β-blockade to be maintained for other aspects of 
its function while recruiting MEF2 pro-survival activity by alternate routes in the acute 
phase.  
Furthermore, it would be interesting to find out if another mechanism of cardiac cell 
death, necroptosis, is regulated by MEF2. Recent studies have shown that necrostatin-1 
(Nec-1) is a chemical compound that inhibits necroptosis without affecting apoptosis 100 
Since Nec-1 reduces infarct-mediated cell death post ischemic/reperfusion 224,therefore 
it is interesting to see if  Nec-1 has an effect on MEF2 transcriptioal activity. In particular 
using a MEF2-Lacz transgenic mice as an in vivo model post MI and to see if this is 
associated with increase in MEF2 pro-survival activity.  
In the second study, the mechanisms of how MEF2 activity is down- regulated during 
chronic β-blockade and determine whether this is protective against pathological heart 
remodeling was investigated. This study indicated that chronic β-blocker treatment 
leads to dynamic changes in the heart failure associated cardiac gene transcriptome, 
and this is accompanied by repression of MEF2 activity. In this category we have 
identified 32 genes that are differentially regulated by TAC whose expression pattern is 
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reversed when the TAC mice are treated with β-blockers. Of particular interest was 
Rarres2 (which encodes Chemerin) an adipokine that was also upregulated in MEF2A 
knockout cardiomyocytes. Previous studies have shown that Rarres2 is associated with 
cardiac apoptosis and coronary artery disease 213. Our experiments revealed that P38 
MAPK/MEF2 regulates Rarres2 in cardiomyocytes through MEF2. Also data from this 
thesis indicates Rarres2 may play a pro-apoptotic role in cardiomyocytes, as siRNA 
mediated depletion of Rarres2 following isoproterenol treatment reduced cleaved 
caspase-3 expression in cardiomyocytes. It would thus be interesting to further study 
MEF2 regulation of Rarres2 in human heart disease. Inhibition of Chemerin binding to 
its receptor or Loss of function analysis of Rarres2 in experimental animal models of 
myocardial infarct and pressure overload would elucidate its function in adult myopathy. 
In our study, we implicated GO terms associated with the immune system, inflammation 
and apoptosis, it would be interesting to further analyze the involvement of these 
inflammatory/immune system genes in human heart disease.  
One other aspect of our data sets that warrants consideration is the identification 
of a number of non-coding RNAs. Some miRNAs such as miR-133 and miR-208 are 
expressed in the mammalian heart and have been linked with the development of 
cardiac hypertrophy in several studies 225,226. Since we know that miRNAs regulate an 
extensive and complex regulatory network of gene expression involving many protein-
coding genes, it will be of interest to determine the extent of miR involvement in the 
gene expression changes involved in heart failure and in response to β-adrenergic 
blockade to understand their role in protection from or progression to heart failure. 
Collectively, these data further define the role of β-blockade on MEF2 regulation in 
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heart, which is important in cardiac muscle gene expression during physiological and 
pathological adaptation of the heart. Activation of MEF2 is necessary for preventing 
cardiac apoptosis and regulation of cardiac survival gene expression in conditions of 
acute β-adrenergic signaling but blockade of chronic β-adrenergic signaling also leads 
to inhibition of myocardial MEF2 activity and also likely contributes to the reversal of the 
effects of heart failure associated transcriptome dynamics. This can, at least partially, 
be explained due to acute and chronic β-adrenergic signalling effects that have been 
associated with the PKA and CaMK signalling pathways, respectively 227, which target 
MEF2 in different ways. The impact of these basic studies for cardiac pathology and 
therapeutics will require many years of further study in additional clinically relevant 
models and in human heart tissue.  
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APPENDIX A 
 
Heart disease: recruitment of MEF2 activity by β−blockers wards off 
cardiomyocyte death χ 
 
             Morbidity and mortality associated with cardiovascular disease is a predominant 
global health problem. Death of cardiac muscle cells (cardiomyocytes) through 
programmed cell death (apoptosis) is one hallmark of the progression to heart failure 
174. Moreover, loss of cardiomyocytes due to myocardial infarction (MI) in patients who 
survive the initial insult is a major determinant of residual heart function and ultimately 
their longer term prognosis. The extent of cardiomyocyte death is thus a primary 
determinant of subsequent left ventricular remodeling and progress to heart failure 129. 
Given that the human heart has virtually no innate capacity for regeneration, the 
mechanisms of cardiomyocyte cell death, and arguably more importantly, the survival of 
these cells and ultimately the salvage of the myocardium, is of profound clinical 
importance. An emergent concept in the report by Hashemi et al. 212 is that a protein 
complex named MEF2, commonly known for its role in the development of the 
cardiovascular system, is linked to cardiomyocyte survival. In addition, the β adrenergic 
signaling pathway that fulfills an extensive role in the physiology and pathology of the 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
χ	  	  S Hashemi1,2,3, S Wales1,2,3, T Miyake1,2,3 and JC McDermott*,1,2,3,4 
 
    1 Department of Biology, 2 Centre for Research in Mass Spectrometry (CRMS), 3  
       Muscle Health Research Centre (MHRC), 4 Centre for Research in Biomolecular  
    Interactions (CRBI), York University. 	  
	   139	  
adult heart is shown to intersect with MEF2’s pro-survival function in cardiomyocytes. 
The initial cue that led to the inception of these studies was accumulating evidence in 
the central nervous system indicating that a primary function of MEF2 in neurons is to 
protect them from apoptosis 17,228 .In view of the fundamental role played by MEF2 in 
the control of cardiac gene expression, 30 it was a logical next step to address the 
question as to whether MEF2 might play a parallel role in the heart. Initially, using 
cultured rodent cardiomyocytes and flow cytometry as a sensitive indicator of apoptotic 
cell death, Hashemi et al. 212 report that levels of cell death are dramatically enhanced 
in cardiomyocytes when the expression of MEF2 is suppressed using siRNA 
technology. Transcriptome analysis of these MEF2 depleted cells correspondingly 
indicated extensive differential expression in an apoptotic gene network suggesting 
therefore that MEF2 does indeed play a key role in cardiomyocyte survival. A further 
clue to the potential importance of these observations came from previous work from 
the same group in which β adrenergic signaling mechanisms were found to directly 
converge on and regulate MEF2 activity 134. Acting through the β adrenergic receptors, 
catecholamines, such as adrenaline or noradrenaline, activate adenylate cyclase which, 
through the classical cAMP signaling pathway, result in activation of Protein kinase A 
(PKA). The striking connection was that the earlier work, in a skeletal muscle system, 
elucidated that PKA phosphorylates the MEF2 protein complex enhancing its interaction 
with a co-repressor (HDAC4), thus inactivating MEF2 function 30,134. Underlying the 
relevance of these observations is the long known sensitivity of the heart to β 
adrenergic stimulation that exerts dynamic physiological control over both chronotropic 
(rate) and inotropic (strength) properties of cardiac contraction. Moreover, high levels of 
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β adrenergic signaling, especially after MI, have been linked with cardiomyocyte death 
in the vicinity of the infarct and also in the more gradual loss seen in progressive heart 
failure 77,174. What has perhaps not been fully appreciated is the connection of β 
adrenergic signaling to the acute and chronic control of myocardial gene expression and 
cell survival. Collectively, these observations framed the next question…Does β 
adrenergic signaling impact MEF2’s pro-survival function in cardiomyocytes? 
Experiments addressing this question indicate that treatment with agonists of the β 
adrenergic system acutely promotes cardiomyocyte apoptosis while concomitantly 
shutting down MEF2 function. A tantalizing additional layer of proof 
is that expression of an engineered form of MEF2 that is resistant to PKA in 
cardiomyocytes renders the cells less prone to apoptotic cell death in response to 
strong β adrenergic activation. Further evidence in this report are ‘proof of principle’ 
experiments using β adrenergic blockers such as Atenolol, which competitively block 
the β1 adrenergic receptors from being activated by its natural ligands (Figure S1). To 
digress momentarily, since the Nobel prize winning development of this class of drugs 
by Sir James Black, 118 β-blockers have truly proved to be a seminal ‘super-drug’, used 
as a front line treatment for progressive heart disease and many other conditions for 
several decades. Enhanced sympathetic drive due to binding of catecholamines to the 
β1 and β2-subtypes of cardiac adrenergic receptors in patients with heart failure is 
inversely correlated with survival indicating one compelling reason why β blockers are 
efficacious in heart disease. In the studies of Hashemi et al 212,  β blockers rescue 
MEF2 function from β adrenergic repression and, in so doing, promote cardiomyocyte 
survival (Figure  S1). It is also pertinent, but as yet unanswered, to consider whether 
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other types of cardiomyocyte death apart from apoptosis, such as autophagy-induced 
cell death and necroptosis, are also impacted by MEF2. Nevertheless, the logical 
extrapolation is to question whether β blockers can be effectively used to enhance 
MEF2 function and promote cardiomyocyte survival under conditions in which their 
survival is compromised, such as during acute and subacute phases after MI. As with 
any basic discovery science, questions of efficacy and relevance to the human condition 
remain. A crucial one being, can timely β blocker treatment after MI and in the subacute 
stages in humans mitigate cardiomyocyte cell death, ventricular remodeling and 
progression to heart failure? Although there is no direct evidence addressing this 
question, one randomized trial reviewed by Sinert et al. 229 demonstrated that β blocker 
treatment within 24 h in patients presenting with elevated ST segment MI did not reduce 
mortality or re-infarction when compared with placebo, indicating that β blockade post 
MI is tolerated with no obvious contraindications for most patients. The impact of this 
treatment modality for longer term cardiomyocyte survival remains to be determined. An 
alternate therapeutic approach might also be tailored drugs that transiently activate 
MEF2 through a different mechanism. No doubt there are myriad hurdles and 
complexities to consider before these observations can be clinically applied. Further 
experimentation in more physiological models and in human heart cells will examine the 
efficacy of these ideas. Moreover, detailed consideration of these findings requires 
further elaboration by clinical colleagues in the context of other treatment modalities and 
other cardiovascular system parameters. 
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 Figure S1 
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Figure S1. β adrenergic/PKA-mediated inhibition of MEF2 contributes to 
cardiomyocyte cell death. On the left side, acute activation of β adrenergic receptors 
invokes cAMP accumulation (yellow triangles) and PKA activation in cardiomyocytes, 
resulting in suppression of MEF2 transcriptional activity by direct phosphorylation and 
nuclear interaction with HDAC4/5. Expression of pro-survival genes such as KLF6 is 
prevented resulting in enhanced cardiomyocyte death. On the right side, β-blockers, 
such as atenolol, competitively inhibit the activation of the β adrenergic receptors and 
downstream signaling resulting in enhanced MEF2 activity, thus promoting 
cardiomyocyte survival. 
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APPENDIX B 
Material and Methods 
 
Transformation  
 
Stock expression plasmids should be diluted to 10ng/µl in a -20 freezer for easy 
transformation.  
- Carrier DNA (has no promoter): Bluescript (pBSK), etc.  
- Marker of transfection: ds Red, GFP.  
- Backbone: pMT2, pcDNA, etc.  
- DNA effectors: Mef2a, mef2d etc.  
 Obtain competent cells: E. Coli XL1Blue. Once thawed, can’t reuse. Thaw on ice. Must 
be grown at a certain OD prior to freezing.   
Add 1 µl (10ng) of expression plasmid to 50 µl of E. Coli. Add plasmid to tube first. 
Pipette up and down once. Incubate on ice for 30 minutes.  
Heat Shock for 1 min at 42oC water bath. Follow up with 2 min on ice. In the meantime 
take out LB plates and warm them in 37-degree room. Put bacterial waste in a 
designated waste.  
At room temperature add 200 µl of LB+0.1%glucose by open flame to the bacteria. Put 
in water bath or incubator at 37oC for 30 minutes. Spin at 7000 rpm for 5 minutes. 
Remove supernatant. Re-suspend in 50 µl LB and plate by an open flame. Place the 
plates facing down at 37 degrees overnight. Next day put in 4oC or select colony and 
proceed with maxi-prep. Keep plates for 1 week. 
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Transfection with Lipofectamine in neonatal cardiomyocytes 
 
For Lipofectamine 2000 (11688, Invitrogen) transfection in primary cardiomyocytes, 
seed the cells at 80% confluence in 6-well plates 24 hours prior to transfection. For 
each well, dilute a total of 2.5 µg of DNA in 150 µl in Opti-MEM medium (31985, 
Invitrogen), and in a separate tube dilute 2.5x of Lipofectamine 2000 reagent in 150 µl 
Opti-MEM medium. Combine the DNA and Lipofectamine mixtures (300 µl), mix and 
incubate for a minimum of 5 min. Add the 250 µl of DNA/Lipofectamine mixture to cells 
in culture medium, incubated at 37°C overnight. Following the incubation, re-feed the 
media and allow the cells to recover for a minimum 24 hours prior to harvesting, and 
pharmacological treatments. 
For Lipofectamine RNAiMAX (Invitrogen), seed the cells at 80% confluence in 6-well 
plates 24 hours prior to transfection. For each well, according to the manufacture’s 
instruction, dilute Lipofectamine RNAiMAX reagent into 150 µl in Opti-MEM medium, 
and in a separate tube, dilute siRNA (100-200nM) in 150 µl Opti-MEM medium, mix and 
incubate for a minimum 5 min at RT. Add the 250 µl of siRNA/Lipofectamine mixture to 
cells and incubate at 37°C overnight. Following the incubation, re-feed the media and 
harvest 48 to 72 hours later for western immunoblotting analysis to determine the 
efficacy of protein knock down or flow cytometry analysis. 
β-galactosidase assay 
 
Per each sample prepare the reaction mixture (500 µl Z buffer, 100 µl ONPG, 2.74 µl β-
mercaptoethanol). Mix 600 µl of the reaction mixture with 100 µl of the cell lysate and 
incubate at RT or for faster result at 370C until the reaction is done and a colour 
changed (yellow) has appeared. To stop the reactions add 300 µl of Na2CO3 to each 
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tube. Measure absorbance of samples at 420 nm using spectrophotometer.  
Luciferase assay 
Luciferase assays were performed with commercially purchased substrate (Promega). 
All reporter assays were performed with cells grown in 35 mm dishes. Cells were 
washed 3X with cold 1X Phosphate buffered saline (PBS). Add 300 µl of luciferase lysis 
buffer (20 mM Tris, pH 7.4, 0.1% Triton-X 100) in each well per dish. Incubate at RT for 
5-10 min.  Scrape cells off with rubber policeman and collect into labeled tubes, vortex, 
spin down cell debris at max speed for 10 min. Collect the supernatant into a new tube 
and freeze lysate until analysis. When ready to analyze, thaw cells and transfer 50/100 
µl to Luciferace assay tubes and use the Berthold Luminometer to detect light units.  
Harvesting Cells (Whole cell extracts)  
Do everything on ice. Aspirate or dump old media out of dish. Wash 2X PBS; Add 700 
µl of PBS onto plate; Scrape into tubes using rubber policeman. Pellet cells: 1.5g for 5 
minutes. Aspirate PBS. Add 100 µl of (or 5x the pellet size) NP-40 lysis buffer or β-gal 
depending on protocol. Pipette up and down to break cells. Vortex for 10 sec, Incubate 
on ice 5 min. Repeat 3X. Spin at max speed 15 min.  Store supernatant at -80oC.  
Lysis Buffer Ingredients:  
 
It includes; PMSF, Sodium Othrovanadate, Protease Inhibitor. Then add to NP-40 lysis 
buffer in 1:100 ratios.  
NP-40 Lysis Buffer: Make up to 100 ml, store at 4oC. 
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Volume  Stock  Take  Final 
Concentration  
250 ml  1 M Tris pH 8.0  5 ml  50 mM  
250 ml  5 M NaCl  3 ml  150 mM  
50 ml  10% NP-40  5 ml  0.5 %  
100 ml  0.5 M EDTA pH 8.0  400 µl  2 mM  
100 ml  0.5 M NaF  20 ml  100 mM  
100 ml  0.1 M Na Pyrophos.  10 ml  10 mM  
 
Protein extracts 
 
Protein samples were kept on ice during the entire procedure. Cells were washed twice 
with cold 1x PBS. After aspirating the last PBS wash, 1.0 mL of cold 1xPBS was added 
to cells. Cells were then gently scraped with a rubber policeman and transferred to a 
new tube and then centrifuged at 1500xg for 5 min at 4°C. After removing the PBS, the 
pellet was diluted with five times its volume in NP-40 lysis buffer (supplemented with 1 
mM Sodium orthovanadate, 1 mM PMSF and Protease inhibitor cocktail (Sigma, P-
8340). Cells were vortexed briefly every 10 minutes for a total of 30-40 min, and 
centrifuged at high speed (>10 000xg) and supernatant was transferred to a fresh tube. 
Protein concentrations were determined by Bradford assay (Bio-Rad) with bovine serum 
albumin (BSA) as a standard. An equal amount of protein was diluted with 4X SDS 
sample buffer and samples were boiled for 5 min, chill on ice and centrifuge to use for 
SDS-PAGE. 
SDS-PAGE 
Prepare resolving gel and then top with stacking gel with appropriate comb inserted in 
Hoefer gel apparatus. Fill bottom and center well of mini-gel apparatus with 1X Laemmli 
buffer. Load equal amount of protein samples on the gel. Run the gel at 100 V through 
stacking and 120 V through running gel. 
Western blotting 
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After SDS PAGE, transfer protein from gel to Immobilon-P (Millipore) membrane by wet 
transfer at 20 V overnight. Block membrane with odyssey blocking buffer (LI-COR) in 
(1:2) PBS/TBS for 1 hour at RT. Incubate membrane with primary antibody diluted 
(1:100-1:1000) in odyssey blocking buffer solution overnight at 4 °C. Wash membrane 
with 1X PBS/TBST with 0.1% Tween 20 (3 X 5 min). Incubate membrane with 
secondary antibody IRDye 680RD at 1:5000 in odyssey blocking solution for 2 hours at 
RT. Wash membrane with 1xPBS/TBST with 0.1% Tween 20 (3 X 10 min) and keep the 
membrane in 1xPBS at 4 °C. The blots were then imaged using LI-COR odyssey 
system. 
Chromatin immunoprecipitation (ChIP) 
 
ChIP experiments followed the guidelines set by EZ ChIP™ (Upsate) with minor 
modifications. Cardiomyocyte cells were fixed with 1% formaldehyde (Sigma) for 15 
minutes at 37°C. Fixing was quenched by Glycine at a final concentration of 0.125 M. 
Cells were collected in PBS containing phenylmethylsulfonyl fluoride (PMSF) (Sigma) 
and protease inhibitor cocktail. Cells were collected at 5000 rpm for 5 minutes at 4°C. 
Cells were lysed using Wash Buffer I (10 mM HEPES pH 6.5, 0.5 M ethylene glycol 
tetraacetic acid (EGTA), 10 mM EDTA, 0.25% Triton X-100, protease inhibitor cocktail, 
PMSF) for 5 minutes on ice. Nuclei were collected and resuspended in Wash Buffer II 
(10 mM HEPES pH 6.5, 0.5 mM EGTA, 1 mM EDTA, 200 mM NaCl, protease inhibitor 
cocktail, PMSF) for 10 minutes on ice. Nuclei were again collected and then treated with 
nuclear lysis buffer (50 mM Tris–HCl pH 8.1, 10 mM EDTA, 1% SDS). Chromatin was 
sheared using a Misonix sonicator to produce 500 bp fragments. Crosslinked sheared 
chromatin was collected following a 15-minute spin at maximum speed. Twenty percent 
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of total chromatin was set aside as input. Sheared crosslinked chromatin was diluted 
1:10 with immunoprecipitation (IP) dilution buffer (0.01% SDS, 1.1% Triton-X 100, 1.2 
mM EDTA, 16.7 mM Tris–HCl pH 8.1, 167 mM NaCl) and incubated with antibody 
overnight at 4°C with rocking. Protein G Dynabeads (Invitrogen) were blocked with 20 
µg salmon sperm DNA in IP dilution buffer (15 µl of beads + 135 µl IP dilution buffer + 
20 µg salmon sperm DNA per IP) overnight at 4°C with rocking. We incubated 152 µl of 
pre-blocked beads with the IP reaction at 4°C for 1 h. Dynabead-bound antibody-
chromatin complexes were washed using IP Wash Buffer I (20 mM Tris pH 8.1, 2 mM 
EDTA, 150 mM NaCl, 1% Triton-X 100, 0.1% SDS) and II (20 mM Tris pH 8.1, 2 mM 
EDTA, 500 mM NaCl, 1% Triton X-100, 0.1% SDS), each incubated for 10 minutes at 
4°C, and followed with two washes in Tris-EDTA (TE) buffer at 4°C. Protein-DNA 
complexes were freed from Dynabeads through the addition of elution buffer (0.1 M 
NaHCO3, 1% SDS) for 30 minutes at RT. To separate protein from DNA, samples were 
treated with 12 µl of 5 M NaCl (BioShop) at 65°C for 4 h or overnight. Protein was 
further degraded by the addition of Proteinase K (Sigma), EDTA, Tris pH 6.5 for 1 h at 
45°C. DNA samples were then purified using a PCR clean up kit (Qiagen, Mississauga, 
ON, Canada). 
Quantitative PCR.  
2.5 µl gDNA or cDNA was combined with SybrGreen (BioRad) and 500 nM primers in a 
final volume of 20 µl. cDNA was diluted 1:10 prior to use. Each sample was prepared in 
triplicate and analyzed using Rotor-Gene Q (Qiagen). ChIP-qPCR: 5min 95oC, [5s 95oC, 
15s 60oC] x 40 cycles. Fold enrichment (ChIP-qPCR) was quantified using the ΔΔCt 
method. 
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APPENDIX C 
Supplementary Materials 
 
 
 
 
 
Figure S2 
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Figure S2. β-AR activation modulates cellular localization of MEF2A in 
cardiomyocytes. Primary cardiomyocytes were treated with solvent or Isoproterenol 
(Iso, 10 µM) alone and in combination with β-blockers Atenolol (Ate, 10 µM) and 
ICI118551 (1 µM). After treatment, cells were fixed with 4% paraformaldehyde and 
immunofluorescence analysis was performed using a primary antibody to MEF2A (red). 
DAPI (4,6-diamidino-2-phenylindole) was used to identify nuclei (blue). The merged 
pictures demonstrate localization of MEF2A (Red) in respect to Isoproterenol (Iso, 10 
µM), β-blockers Atenolol (Ate, 10 µM) and ICI118551 (1 µM) treatment, counterstained 
with DAPI. Scale represents 20 µm. 
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Figure S3 
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Figure S4. Baseline echocardiography analysis before administration of Atenolol or 
solvent. Mean ± S.E.M (n=18), t-test was used, *P<0.05 vs. Sham+Sol.  
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Figure S5. Heart failure associated changes in lncRNA expression. A mouse lncRNA 
database containing 2073 lncRNA genomic positions was obtained from Matkovich et 
al. 189. Short paired-end reads from 12 in vivo samples were mapped with RSEM/ 
Bowtie to the reference index which was built for the 2073 mouse lncRNAs (mm9). All 
uniquely mappable short reads are included by using the bowtie-m 1 option in the rsem-
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calculate-expression command. A) Significant fold changes for 84 lncRNA (FDR<0.2; 
red upregulated; blue downregulated). lncRNA are sorted by p-value based on the left-
most column. The three columns in the left part of the figure show fold changes with 
respect to reference condition Sham+Sol. The next two columns show the significance 
of fold changes in TAC+AT with respect to reference conditions TAC+Sol and 
Sham+AT, respectively. B) The percentages of reads which mapped to lncRNAs varied 
in a narrow range from 2.8% to 3.4% C) The number of differentially expressed 
lncRNAs per condition. D) The five most abundant lncRNAs in each treatment. E) DE 
lncRNAs targeted in both TAC+Sol vs Sham+Sol and TAC+AT vs TAC+Sol.  
 	  	  	  
 
 
 
 
 
 
 
 
 
 
 
	   156	  
 
  
 
 
 
Figure S6.  Expression of genes upregulated in TAC and down regulated with Atenolol 
treatment (Figure 19C), was confirmed using qRT-PCR.  Data were normalized to 
Gapdh and are presented as fold change using the delta delta Ct method (n=3, *P<0.05 
**P<0.01  Sham+Sol vs TAC+Sol, +P<0.05  ++P<0.01 Sham+Sol vs Sham+AT, 
##P<0.01 TAC+Sol vs TAC+AT).  
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Figure S7.  Expression of genes down-regulated in TAC and upregulated with Atenolol 
treatment (Figure 16C), was confirmed using qRT-PCR. Data were normalized to 
Gapdh and are presented as fold change using the delta delta Ct method (n=3, 
**P<0.01  Sham+Sol vs TAC+Sol, +P<0.05 ++P<0.01 Sham+Sol vs Sham+AT, #P<0.05 
TAC+Sol vs TAC+AT).  
 
 
 
!"
!#$"
!#%"
!#&"
!#'"
("
(#$"
(#%"
(#&"
!"#$%!&'( )*+%!&'( !"#$%*)( )*+%*)(
),$-.(
/&
'0
(+
"#
12
3(
!"
!#$"
!#%"
!#&"
!#'"
("
(#$"
(#%"
(#&"
!"#$%!&'( )*+%!&'( !"#$%*)( )*+%*)(
!',-.#/(
0&
'1
(+
"#
23
4(
!"
!#$"
!#%"
!#&"
!#'"
("
(#$"
!"#$%!&'( )*+%!&'( !"#$%*)( )*+%*)(
,-.'/(
)"
**"
++"
0&
'1
(+
"#
.2
3(
!"
#$
%&
'(
)*
+%
!"
!#$"
%"
%#$"
&"
&#$"
'"
'#$"
("
,'(-.,"#% /0&.,"#% ,'(-.0/% /0&.0/%
&"#1(%
)"
!"
#"
$"
%"
&"
'"
("
!"#$%!&'( )*+%!&'( !"#$%*)( )*+%*)(
,-&.(
/&
'0
(+
"#
12
-(
!"
#"
$"
%"
&"
'"
("
!"#$%!&'( )*+%!&'( !"#$%*)( )*+%*)(
,-./0(
-&
'1
(+
"#
23
4(
)"
!"
!#$"
!#%"
!#&"
!#'"
("
(#$"
!"#$%!&'( )*+%!&'( !"#$%*)( )*+%*)(
,-./0(
1&
'2
(+
"#
34
5(
))" **"
!"
#"
$"
%"
&"
'"
("
)"
!"#$%!&'( )*+%!&'( !"#$%*)( )*+%*)(
+&',(
-&
'.
(+
"#
/0
1(
*"
	   158	  
 
 
 
 
 
 
 
 
Figure S8. Primary cardiomyocytes were transfected with two independent siRNAs, 
Alas2 siRNA and Iigp1 siRNA or with scramble siRNA control and treated with 
isoproterenol  (10µM) for 48 hours.  Equal amounts of total protein were used for 
western blot analysis and the levels of the indicated proteins were assessed by a 
standard immunoblotting technique using specific primary antibodies for each as 
indicated. 
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Figure S9. Predicted MEF2 consensus sequences from 32 overlapping genes in Figure 
16D. RNA expression (FPKM) of these genes in heart muscle (Female, age 40-50) 
were analyzed in Human Protein Atlas program. 
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